









How does sevoflurane induction, 
followed by a ketamine maintenance 
infusion affect intraocular pressure? 
Establishment of a protocol for paediatric 
glaucoma examinations under anaesthesia.
Dr Jessica Gwendoline van der Walt 
MBBCh, DCH, DA, FCA (SA)
Department of Anaesthesia
University of Cape Town
SMTJES001
Submitted in partial completion of the degree
Master of Medicine in Anaesthesiology





Department of Anaesthesia, 
University of Cape Town 










The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 












2 | D r  J e s s i c a  v a n  d e r  W a l t  – M M e d  D i s s e r t a t i o n  
 
Abstract 
How does sevoflurane induction, followed by a ketamine maintenance infusion affect 
intraocular pressure? 
 
Establishment of a protocol for paediatric glaucoma examinations under anaesthesia. 
 
Purpose: 1.To determine the effect of sevoflurane induction, followed by intravenous 
(IV) ketamine infusion on intraocular pressure (IOP) in the paediatric glaucoma 
population.  2. To establish the earliest time point at which IOP measurement most 
closely resembles awake values.  
Methods: A prospective, descriptive study of the IOP changes occurring in 25 
children requiring IOP measurements at our institution. A standardised anaesthetic 
technique was employed; sevoflurane induction, intravenous cannulation, ketamine 
bolus (2mg/kg) and maintenance (4mg/kg/hr) for 15 minutes. IOP measurements and 
physiological variables were recorded after sevoflurane induction, then every 2 
minutes for a period of 10 minutes, one at 15 minutes as well as 5 minutes after 
ketamine discontinuation.   
Results: IOP was measured in 25 patients (50 eyes). Twenty-six eyes (52%) had 
glaucoma. The mean patient age was 29 months (range 2-88 months). The mean 
IOP after sevoflurane induction was 3,68mmHg lower than that with ketamine 
maintenance (sevoflurane eliminated) (95% CI 1,35 to 6,02mmHg) (p=0,002)). 
Physiological variables return to baseline at 8 minutes, which correlates with the time 
taken for sevoflurane to be eliminated from exhaled gas. The difference in IOP 
between ketamine anaesthesia (time 15 minutes) and near wakefulness was only 
0,28 mmHg (95% CI -2,23 to 2,79mmHg) (p=0,826). Mixed effects models showed 
similar trends but a higher baseline (7,85mmHg (6,19 to 9,51mmHg) (p<0,001)) in 
those with glaucoma when compared to those without.  
Conclusion: Sevoflurane lowers IOP significantly when compared to ketamine 
anaesthesia. While eyes with glaucoma had a higher baseline than those which did 
not have glaucoma, both groups follow similar trends in response to the anaesthetic 
agents. This standardised anaesthetic protocol allows reliable IOP measurement 15 
minutes after termination of sevoflurane and commencement of ketamine infusion, 
with no reported adverse events.  
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ASA: Anaesthetic Society of Anaesthesiologists physical status classification 
system 
BIS: Bispectral Index 
Bpm: beats per minute 
CI: confidence intervals 
Cisat: cisatracurium 
CO2: carbon dioxide 
Dex: dexmedetomidine 
EMLA: eutectic mixture of local anaesthetics (lignocaine 2,5% and prilocaine 2,5%) 
EUA: examination under anaesthesia 
g: grams 
GA: general anaesthesia 
HR: heart rate 
hr: hour 
IM: intramuscular 
IOP: intraocular pressure 




l/min: litres per minute 
LMA: laryngeal mask airway 
max: maximum 
MBP: mean blood pressure 
10 | D r  J e s s i c a  v a n  d e r  W a l t  – M M e d  D i s s e r t a t i o n
mcg: micrograms 
mcg/kg: micrograms per kilogram 
mcg/kg/hr: micrograms per kilogram per hour 
mg: milligrams 
mg/kg: milligrams per kilogram 
mg/lb: milligrams per pound 
midaz: midazolam 
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O2: oxygen 
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SD: standard deviation 
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Std dev: standard deviation 
yrs: years 
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Part A: Research Protocol 
How does sevoflurane induction, followed by a ketamine maintenance infusion affect 
intraocular pressure? 
 
Establishment of a protocol for paediatric glaucoma examinations under anaesthesia. 
 
Dissertation for Master of Medicine in Anaesthesiology 
Introduction and Overview: 
Integral to the management of glaucoma is the accurate measurement of intraocular 
pressure (IOP). Examination under anaesthesia (EUA) is required for accurate IOP 
measurement in children under 3 years of age, or the uncooperative child, as awake 
IOP measurements are poorly tolerated. 
Success rates for awake IOP measurements in cooperative, sedated patients is 
variable. Physiologically these measurements may be elevated in an anxious child 
due to elevation in central venous pressure, contraction of the extraocular muscles 
or an increase in the choroidal blood volume(1). Shah et al warn against 
measurement of IOP in awake patients even if they are cooperative, due to 
unintentional squeezing of the eyelids(2). 
All anaesthetic agents available for sedation or EUA may influence intraocular 
pressure. Titration of midazolam to clinical effect (drooping of eyelids) causes a 
significant reduction in intraocular pressure(2). Dexmedetomidine has been shown 
to reduce intraocular pressure (3-5). Chloral hydrate has been shown not to 
influence intraocular pressure (6), and has been shown to have a 93,7% success 
rate for sedation in ophthalmic procedures (7) but is no longer available at our 
institution as it has been removed from the Essential Drug List. All volatile 
anaesthetic agents, including sevoflurane, have been shown to reduce intraocular 
pressure(8) as have the opioid class of drugs(9). 
No single best anaesthetic technique has been described for these examinations 
under anaesthesia. Several confounding factors make the literature difficult to 
interpret. It is not clear whether results from a population without glaucoma can be 
extrapolated to those who do have glaucoma. The type of surgery that the study 
population is undergoing may also influence the results. There are studies reflecting 
the effects of ketamine induction (intramuscular) followed by sevoflurane(10), 
sevoflurane vs ketamine(11), ketamine alone(12) and halothane with ketamine(13) 
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but no studies have looked at the effects on IOP of sevoflurane induction followed 
by ketamine sedation. 
The effect of ketamine on IOP has been widely debated. Recently is has been 
shown that ketamine, at doses less than 4 mg/kg, doesn’t cause a clinical 
meaningful elevation in IOP(10). This was also suggested by Nagdeve et al (14). 
They found an increase in intraocular pressure when 6mg/kg of ketamine was 
administered but not when a lower dose was given. 
 
Rationale and Justification 
There is to date no data on the effects on IOP of a standardised anaesthetic 
technique for EUA using sevoflurane for induction followed by intravenous (IV) 
ketamine maintenance. Current anaesthetic practise at Red Cross Children’s 
Hospital is varied, with no standardization of technique or timing of intraocular 
pressure measurements. Common practice is to induce anaesthesia with 
sevoflurane to allow placement of an IV cannula followed by ketamine to maintain 
anaesthesia. IV cannulation is notoriously difficult in young children and topical 
anaesthetic cream is not freely available and takes time to achieve good effect.  
Furthermore, the sympathetic stimulation caused by a difficult IV cannulation in an 
awake, uncooperative child may itself elevate intraocular pressure.  
Al-abrak et al (15) emphasised that standardisation of all aspects of the anaesthetic 
is required in order to achieve reliable, repeatable results. Aileen Adams (13) said, 
‘It would seem wise that any individual child should always be examined under the 
same anaesthetic agent if truly comparable readings are to be obtained.’   
We propose a standardised anaesthetic technique, evaluating changes in IOP over 
time validating our current clinical practice in order to obtain IOP measurements 
under EUA that are repeatable and closely reflect awake values.  
 
Aims: 
1. To determine the effect of sevoflurane induction, then IV ketamine maintenance 
infusion on intraocular pressure in paediatric glaucoma EUA. 
2. To establish the time point at which IOP measurement most closely resembles 
awake values.  
 
13 | D r  J e s s i c a  v a n  d e r  W a l t  – M M e d  D i s s e r t a t i o n  
 
3. Establishment of a standardised anaesthetic technique for future EUAs at Red 
Cross War Memorial Children’s Hospital. 
 
Method: 
A prospective, descriptive, observational study of the IOP changes over time in 25 
children (50 eye measurements) requiring IOP measurements using a standardised 
anaesthetic technique. 
Inclusion criteria: 
ASA 1-2 children requiring EUA for IOP measurement 
Age 0-3 years or unable to cooperate for awake measurements. 
Day case surgery 
Exclusion criteria: 
Contraindication to sevoflurane / ketamine anaesthesia 
Difficult airway 
ASA 3-4 
Standardised anaesthetic technique:  
 Normal fasting guidelines: Clear fluids up to 2 hours before surgery, 
milk/solid food >6 hours before surgery, breastmilk >4 hours before 
surgery 
 No premedication 
 Routine intra-operative monitoring & anaesthetic record keeping 
 Gas induction with Ayers T-piece, 100% oxygen @ 5 l/min and 
sevoflurane, gradually increased and limited to 6% until placement of 
intravenous cannula  
 Maintenance of anaesthesia with an IV ketamine bolus: 2 mg/kg 
followed by an IV ketamine infusion of 4mg/kg/hr for 15 minutes 
using an Alaris PK syringe driver with a 20ml BD plastic syringe 
 Should additional sedation be required further boluses of 1 mg/kg IV 
ketamine may be given 
 Spontaneous ventilation should be maintained with nasal prong 
oxygen @ 4 l/min with and end tidal CO2 & sevoflurane 
measurement. 
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Alternative & rescue airway management on anaesthetist’s discretion 
Glycopyrrolate 10 mcg/kg for excessive secretions (on anaesthetist’s 
discretion) 
 
Should ongoing surgery be required, the anaesthetic technique employed should be 
at the discretion of the attending anaesthetist. 
Post-operative recovery and monitoring as per normal practice. 
 
Intraocular pressure (IOP) measurements: 
 Single operator 
 IOP measurement both eyes, every time, irrespective of whether eye is 
diseased or normal – 10 seconds/eye 
 Perkins applanation tonometer is gold standard 
Data Collection and Capture: 
 Preoperative demographic data recorded: age (months), weight (kg), 
pulse(beats per minute), blood pressure(mmHg) 
 Time to intravenous cannulation and first IOP measurement 
 Total sevoflurane administered ( total dose, dose/kg ,dose/kg/min) 
 Total ketamine administered (total dose at each measurement time interval, 
initial bolus, repeat boluses, total infused dose, total dose/kg) 
 Heart rate and  blood pressure (systolic, mean, diastolic) at each IOP 
measurement interval to compare with and see at which point they return to 
pre-operative baseline values 
 Assessment intra- and post-operatively for any complications. 
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IOP measurement intervals and data capture: 
 Just prior to placing the intravenous cannula with only sevoflurane 
administered, no possible sympathetic effect of siting cannula or 
ketamine (Time 0) 
 Two minutes after start of ketamine anaesthesia and discontinuation of 
sevoflurane anaesthetic. 
 Every 2 minutes thereafter for 10 minutes, then at 15 minutes. 
 After 15 minutes the ketamine infusion is stopped and final measurement 
is taken at 20 minutes. 
 
Thus IOP measurements taken at 0, 2, 4, 6, 8,10,15,20 min  
Please see Part D for Data Collection Form 
 
Proposed Statistical Method  
This is a prospective observational study and analysis will be descriptive in nature.  
The aim is to assess the change in intraocular pressure over time, using a 
standardised anaesthetic technique.  In 3 previous studies, sample sizes were 8, 25 
and 30 respectively.  In the last study, 2 groups of 15 patients were randomised to 
two different anaesthetic interventions.  In that study, there was no basis for a 
formal sample size calculation, but the investigators demonstrated significant 
differences in intraocular pressure at specified time points.  Based upon these 
investigations, a sample size of up to 30 patients (60 eye evaluations) in the current 
observational study was regarded as likely to provide adequate statistical power.  
The aim is to plot the physiological variables against time, and obtain an estimate of 
the effects of the anaesthetic agents on intraocular pressure. 
Generalised estimating equations will be used to describe changes in heart rate and 
blood pressure at each time point (0, 2, 4, 6, 8, 10, 15 and 20 minutes, see 
Methods, above) from the preoperative values. This will help us to see the effects of 
our drugs on these variables as well as possibly help identify a point at which our 
variables are not statistically different from preoperative values.  During 
anaesthesia, the time at which heart rate and blood pressure return to pre-induction 
levels, will be considered an appropriate time for intraocular pressure values to 
reflect pre-operative values. 
Comparisons will be made between all parameters using the Student’s paired t-test 
should data be normally distributed, and the Wilcoxon signed-rank test in the event 
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of non-normal distribution.  These tests will be used to compare heart rate and 
blood pressure pre-induction values to those taken when end-tidal sevoflurane 
concentration returns to zero.  The intraocular pressure at this time point will be 
assumed to approximate preoperative intraocular pressure.   
Research Ethics: 
Risks and benefits: 
Standardization of current practice for paediatric glaucoma patients requiring EUA. 
No additional risk factors are anticipated, patients may benefit from increased level 
of observation and presence of additional trained anaesthetic personnel.  
Consent: 
Consent for surgery and general anaesthesia shall be obtained by the ophthalmic 
surgeon and anaesthetist performing the procedure as per standard hospital 
practice. Parental information and consent will be discussed by the investigator 
present. Adequate time will be given for questions and consideration, written 
informed consent obtained, and withdrawal permitted at any time prior to induction 
of anaesthesia. (See Part D – Participant information and consent) 
Privacy and confidentiality 
Participants will be allocated a study number, indicated on data collection form. All 
data will be collected on this form protecting patients’ privacy. Completed Patient 
Data Collection Form, and Consent will be securely stored in the Anaesthetic 
Department. Digital data (Excel spread sheet) will only record study number and will 
be password protected. 
Amendments 
On 19 June 2014 aproval was granted from the Human Resources and Ethics 
Committee to extend our study period beyond 6 months as well as to include 
children older than 36 months should they be unable to cooperate for awake 
measurements. 
Cost and Budget 
No additional time is required for performance of the study, as all data will be 
collected by investigators during the normal process of providing anaesthesia. 
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No additional costs as all disposables are used as part of normal clinical practice 
 
Investigators  
Study will be conducted at Red Cross War Memorial Children’s Hospital, 
Departments of Anaesthesia and Ophthalmology, University of Cape Town. 
Dr Francois Roodt, Specialist Anaesthetist (Principal Investigator) 
Dr Jessica Gwendoline Van Der Walt (Senior Registrar and Co-investigator) 
Dr Chris Tinley (Co-investigator) 
 
No conflict of interests to declare, no sponsorship from trade. 
 
Original accepted protocol , communication, amendments and study 
extension, as well as data collections and consent forms can be found in the 
supporting documentation in Part D.  
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Part B:  Structured Literature Review 
 
Literature Search Strategy 
This literature review was done using PubMed and Google Scholar. Search terms 
were glaucoma, intraocular pressure, paediatric, anaesthetic agents. Searches were 
also done using the names of specific agents. Searches were limited to human 
studies. Adult studies were included due to the small volume of paediatric literature 
available. Exclusions were animal studies and those where there was not at least an 
English abstract. Several studies were found from reading references from those 
studies produced by original searches.  
 
Introduction 
Normal intraocular pressure is 16mmHg +/- 5mmHg.  It has diurnal variation of 2-
3mmHg with pressures peaking in the early hours of the morning(1). In children with 
no intraocular pathology, intraocular pressure has been shown to be much lower 
than in adults.  These pressures tend to increase with age, reaching normal adult 
values at around 12 years of age(2). 
Maintaining appropriate intraocular pressure is vital as this maintains a constant 
corneal curvature and a constant refracting index.  Intraocular pressure is 
considered pathological when it is elevated above 25mmHg although there has 
been a suggestion that since intraocular pressure is generally lower in children, 
even values of 17-20mmHg are far beyond the physiological limits for this 
population. (2) 
Paediatric glaucoma is a rare condition. Children present with elevated intraocular 
pressure which may lead to blindness.  It can be classified as primary congenital 
glaucoma or secondary glaucoma. 
In primary congenital glaucoma the elevation in intraocular pressure is caused by 
obstruction to the outflow of aqueous humour resulting from a developmental 
abnormality of the angle formed between the peripheral cornea and the iris.  
Secondary glaucoma can be either congenital or acquired and can be related to 
ocular or systemic diseases such as Sturge-Weber Syndrome. 
Accurate measurement of intraocular pressure (IOP) is central to the management 
of paediatric glaucoma.  This is generally surgical in primary congenital glaucoma 
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and medical in secondary glaucoma. Some of the surgical techniques described 
include goniotomy in which part of the angle is excised to improve drainage or 
trabeculectomy to improve filtration of aqueous humour. Medical management 
includes the use of topical beta-blockers and topical carbonic anhydrase inhibitors 
(3, 4). 
Objectives of Review 
This review will briefly examine the physiology and pathophysiology of glaucoma, 
current measurement strategies, the feasibility of awake measurements and the 
influence of anaesthetic agents on intraocular pressure.  
1. Physiology and pathophysiology of glaucoma 
Intraocular pressure is determined by forces within the eye exerted outwardly 
through the cumulative effects of the aqueous humour volume, choroidal blood 
volume and the vitreous humour volume.  It is also influenced by external forces that 
exert inward pressure on the globe, including the extraocular muscle tone, 
compression on the globe, as well as scleral compliance(1). 
The volume of aqueous humour is determined by the volume of aqueous humour 
produced as well as the rate of elimination of aqueous humour from the anterior 
chamber of the eye.  Aqueous humour is produced by the epithelial cells on the 
ciliary body through an active secretory process involving carbonic anhydrase.  This 
is secreted into the posterior chamber of the globe from where it circulates into the 
anterior chamber.   The aqueous humour leaves the anterior chamber through the 
trabecular meshwork in the angle between the peripheral cornea and the iris.  
Drainage through the trabecular meshwork is determined by Hagen-Poiseille’s Law. 
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Figure A: Illustration of the sites of formation, circulation and drainage of aqueous 
humour 
This illustration is taken from Cunningham et al’s article (1), ”Intraocular pressure - 
physiology and implications for anaesthetic management.” Can Anaesth Soc J. 
1986;33(2):195-208. 
The choroid’s blood volume is influenced by autoregulation, blood flow through the 
choroid will remain constant within a range of perfusion pressures (90 to 130 
mmHg). Choroidal blood volume is influenced by hypercarbia, hypoxia, changes in 
alkalinity and temperature (1). 
The tone of the extraocular muscles is controlled neurogenically by the central 
nervous system, which is in turn influenced by systemic hormonal as well as 
haemodynamic changes (1). 
2. Intraocular Pressure Measurement  
Intraocular pressure is measured using applanation tonometry.  The principle is that 
the pressure within a fluid filled sphere is equal to that required to flatten part of its 
boundary membrane(1).  The current gold standard for tonometry is the Goldmann 
applanation tonometer.  A high degree of cooperation is required by the patient as 
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topical anaesthetic drops are instilled and the patient must supress the natural reflex 
to move back or blink during the measurement.  This can lead to repeated attempts 
at measurement, prolonged examination times and much distress to both the young 
patient and their family. 
A Perkins’ tonometer is a handheld version of the Goldmann applanation tonometer.  
This is a suitable reference measure for patients in a supine position.  
The iCare rebound tonometer is a new handheld device for measuring intraocular 
pressure. It is more accepted by the paediatric population as no topical anaesthetics 
are required, it uses minimal force – often not even triggering a blink reflex and 
takes its measurements within 0.1 seconds. However, there is poor agreement 
between rebound tonometer measurements and the Goldmann applanation 
tonometer in children with glaucoma.  Rebound tonometry overestimates intraocular 
pressure, thus while a ‘normal’ intraocular pressure could be reassuring, children 
with elevated intraocular pressure would still require more invasive measurements 
or examination under anaesthesia before dramatic management decisions could be 
made. (5) 
3. The Feasibility of Awake Measurements 
One could consider taking these awake in cooperative children. However, 
physiologically these measurements may be elevated in an anxious child due to an 
elevation in central venous pressure, contraction of the extraocular muscles and an 
increase in the choroidal blood volume(3). 
Sihota et al (2) determined awake intraocular pressures in 405 cooperative, 
unsedated children using a handheld Perkins applanation tonometer.  Notably, their 
success rate was only 50-60% in the 1-3 year age group, higher in younger and 
older children.  Some measurements were taken when children were physiologically 
asleep, others after ensuring ideal conditions of quietness and with the cooperation 
of a parent who held the child on his or her lap. 
Of the 35 patients eligible to be enrolled in Oberacher-Velten et al’s study (6) aged 6 
months to 2 years, only 5 were able to cooperate for measurement of intraocular 
pressure with a Perkin’s applanation tonometer without sedation. Most recently, 
Shah et al (15) warn against measurement of intraocular pressure in awake 
paediatric patients even if they are cooperative.  
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4. The Effect of Anaesthetic Agents on Intraocular Pressure
A thorough understanding of physiological and pharmacological influences on 
intraocular pressure are required to provide an anaesthetic with translatable 
measurements to awake pressures.  
Sedation: 
Chloral hydrate, one of the oldest sedatives with a well-established safety profile(7) 
is no longer available at our institution. In a study done by Jaafar et al (8), 
intraocular pressures were measured in 50 awake, cooperative children with normal 
eyes and 10 children with glaucoma.  The measurements were then repeated after 
administration of chloral hydrate. No clinically or statistically significant changes in 
intraocular pressure were noted after chloral hydrate administration in either normal 
or glaucomatous eyes. A recent review of chloral hydrate sedation for paediatric 
ophthalmic procedures showed a 94,2% success rate for sedation after a single 
dose of chloral hydrate(9). Chloral hydrate has a very bitter taste often necessitating 
rectal administration.  Also, it has a long duration of action (up to 8 hours) as well as 
an active metabolite, trichloroethanol, with a prolonged half-life, reducing its 
titratability and suitability for outpatient procedures.(6)  
Midazolam is the most commonly used drug for procedural sedation in both children 
and adults.  It is a short acting benzodiazepine which provides potent sedation, 
anxiolysis and amnesia. Many trials have been done confirming the safety and 
efficacy of this drug(7).  
The effects of midazolam on intraocular pressure have been extensively debated. 
Older trials by Fragen et al (10) as well as Gobeaux et al(11) both found significant 
reductions in intraocular pressure when intravenous midazolam was given to adult 
patients without intraocular hypertension. 
Oberacher-Velten et al (6) found no significant difference in intraocular pressure 
when cooperative children were sedated with oral midazolam. In adults, no 
statistically significant reduction in intraocular pressure was found by either Virkkila 
et al (12,13) with intramuscular midazolam, or Carter et al (14) with intravenous 
midazolam used as an anxiolytic. 
These findings are in contrast to those recently published by Shah et al(15) where 
intraocular pressure dropped significantly after titration of midazolam to clinical 
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effect in awake, cooperative children. Although the average total dose of midazolam 
is not stated, it would seem that a higher dose of midazolam was used in this study. 
This study showed a significant reduction in intraocular pressure in cooperative 
patients after titration of midazolam to clinical effect (eyelid drooping). This has been 
attributed to complete loss of the squeezing action of the eyelids(15).  
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Table A: Summary of Trials on the Effect of Midazolam on Intraocular Pressure 



































































0,7 (p<0,0001)  
Cataract 



















IOP measured in 
non-operative eye 





IOP in either 
group 
Cataract 








(13) 1994 Adult 90 Cataract 





















surgery, prior to 






































27 | D r  J e s s i c a  v a n  d e r  W a l t  – M M e d  D i s s e r t a t i o n  
 
   






















saline given as 
a premed (20 
in each group) 
IOP measured @ 
baseline, 5,10 and 
15 min after 
admin of midaz or 





the two groups 
(p=0,78) 
Any patients 





























before, 15 and 30 
min after 
premedication and 
5 and 15 minutes 


















gical surgery  






























awake and then 
after titration of 
midazolam to 
clinical effect. 
Further drugs and 
measurements 






























28 | D r  J e s s i c a  v a n  d e r  W a l t  – M M e d  D i s s e r t a t i o n  
 
 
The unique sedative state produced by dexmedetomidine, a highly selective alpha2 
agonist, makes it an attractive option for paediatric procedural sedation with minimal 
side effects (16).   
Dexmedetomidine has clearly been shown to reduce intraocular pressure prior to or 
without additional general anaesthesia. This is summarized in Table B. Virkkila et al 
(13) and Abdalla et al’s (17) studies were done in adult patients undergoing cataract 
surgery under regional anaesthesia. Jaakola et al (18) and Mowafi et al (19) found a 
reduction in intraocular pressure after infusion of dexmedetomidine before induction 
of general anaesthesia. They also both found that dexmedetomidine blunted the 
haemodynamic as well as intraocular response to endotracheal intubation. This was 
confirmed in Lee et al’s study (20). Xu Lili et al’s study (21), the only paediatric 
study, demonstrated no difference in intraocular pressures measured after induction 
with sevoflurane and again 10 minutes after a dexmedetomidine infusion, during 
which time the patient had received further intravenous drugs and endotracheal 
intubation had occurred. 
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Table B: Summary of Trials on the Effect of Dexmedetomidine on Intraocular Pressure 
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Premedication: 
Midazolam can be administered orally or intranasally. Its effects on intraocular 
pressure have not been conclusively determined. (See earlier notes) 
Intranasal dexmedetomidine significantly reduces intraocular pressure. (See earlier 
notes.) 
Oral, intranasal or intramuscular ketamine and anticholinergics are discussed in 
detail below.  
General Anaesthesia: 
General anaesthesia is considered for obtaining intraocular pressure measurements 
in uncooperative patients. This is a review of current knowledge of the influence of 
volatile anaesthetics, specifically sevoflurane, ketamine and other common 
anaesthetic adjuvants on intraocular pressure. 
It has been well established that volatile anaesthetic agents significantly lower 
intraocular pressure. The reason for this effect is widely debated. Some suggested 
mechanisms are depression of the central nervous system’s intraocular pressure 
control centres, relaxation of extraocular muscle tone, effects on the general 
circulation, ventilation, metabolism and  the impact of agents on the balance 
between the production and outflow of aqueous humour(22, 23).  Due to the rapid 
changes in intraocular pressure after sevoflurane administration, mechanisms other 
than the effects on aqueous production and outflow are more likely. Artru et al (24) 
noted a dose dependant decrease in scleral compliance with increasing 
concentrations of sevoflurane, the effect of which is too small to significantly 
influence intraocular pressure. 
Much early work on the effects of volatile anaesthetic agents on intraocular pressure 
was done by Ausinsch et al (25).  In 1975 they found that intraocular pressure 
measured under anaesthesia with halothane or isoflurane did not differ significantly 
from that taken in sedated, cooperative children. Confounding this work however, 
was the fact that a heavy sedation regime was used to acquire preoperative 
measurements, including pentobarbital with or without pethidine, which itself was 
likely to have reduced intraocular pressure. Those who were only sedated with 
chloral hydrate were uncooperative and did have significantly lower intraocular 
pressure after administration of volatile anaesthesia. 
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An overall decrease in intraocular pressure in children with glaucoma under 
halothane anaesthesia was found by Ausinsch et al in 1977 (26). The response of 
glaucomatous eyes appeared less predictable than that noted in prior studies on 
eyes which did not have glaucoma. Three eyes showed no change in intraocular 
pressure and a slight increase in intraocular pressure was found in 3 eyes. In 5 
glaucomatous eyes intraocular pressure decreased below 25mmHg and in one eye 
below 21mmHg. It was thus noted that the finding of a normal intraocular pressure 
does not preclude the absence of glaucoma. Once again, the control measurements 
were taken under sedation with pentobarbital, meperidine and atropine.  
When examining studies specific to the paediatric population, awake intraocular 
pressure measurements are difficult to acquire. Yoshitake et al (27) measured 
intraocular pressure in children receiving sevoflurane anaesthesia. He found no 
significant difference in intraocular pressure measured during maintenance of 
anaesthesia when compared to baseline. However, baseline measurements were 
taken just after induction and were influenced by sevoflurane. Dominguez et al (28) 
showed a 10% reduction in intraocular pressure in children given sevoflurane 
anaesthesia using a linear regression equation.  Their recommendation was to read 
intraocular pressure when the patient is quiet, sevoflurane is almost fully eliminated 
and the Bispectral Index (BIS) value represents light anaesthesia.   
A review by Pun et al (29) describes a series of 679 paediatric patients who 
received intravenous ketamine anaesthesia for ophthalmic procedures. In this series 
ophthalmic surgery was carried out safely without need for resuscitation or 
intubation. 
Intramuscular injection of ketamine has been described as the simplest way to 
provide optimal conditions for measurement of intraocular pressure. Concerns with 
using this mode of administration include bioavailability, variability of uptake due to 
variable blood supply at the injection site as well as an inability to titrate the drug to 
effect. Lei Wu et al (30) found that intramuscular ketamine used for intraocular 
pressure measurement was strongly associated with increased odds of respiratory 
complications when compared to intravenous ketamine. (Odds ratio 6,78; p=0,02) It 
was felt that it is advantageous to be able to titrate intravenous ketamine to 
adequate anaesthetic depth which overall results in lower doses of ketamine being 
administered, on average 8mg/kg intramuscularly vs 2,75mg/kg intravenously. Also, 
the imprecision of intramuscular administration may result in inadvertent 
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administration of the drug close to a capillary bed resulting in higher than intended 
peak concentrations due to more rapid absorption of the drug. 
The debate as to ketamine’s effect on intraocular pressure has been present since 
the drug was first described as CI-581. The earliest studies showed that ketamine 
elevated intraocular pressure. Corssen et al (31) found that intraocular pressure 
was elevated in the paediatric population of their study (15 cases) after 
administration of ketamine, with a pooled mean increase in intraocular pressure of 
3mmHg from control readings.  
This study had several limitations. It looked at patients of various ages undergoing 
general anaesthesia for various types of surgery without standardization of 
premedications and with considerable variation in pressure readings between eyes, 
within participants and between participants. Also, measurements were taken 3 
minutes after drug administration, inappropriate when the pharmacokinetics of 
ketamine are considered.  
Yoshikawa et al (32) reported that ketamine elevated intraocular pressure in 
children. Interestingly, they managed to take awake pressure readings by ‘training’ 
their patients for three days prior to surgery to relieve their anxiety.   
Adams (33) described an elevation in intraocular pressure when 10mg/kg of 
ketamine was administered intramuscularly to children who had initial readings 
taken under halothane anaesthesia. Adams (33) also noted that the changes in 
glaucomatous eyes were inconsistent, there was a slight rise in intraocular pressure 
in 2 of the 9 children with glaucoma but in the other 7 children intraocular pressure 
fell or remained the same. Adams (33) concluded that intraocular pressure under 
ketamine may be closer to awake values than that taken under inhalational 
anaesthesia, which is associated with muscle relaxation.  
Others have found that ketamine has very little effect on intraocular pressure, 
particularly if patients are well premedicated. Both Peuler et al (34) and Badrinath et 
al (35) examined intraocular pressure in premedicated adult patients undergoing 
elective non-ophthalmic surgery after induction with 2mg/kg intravenous ketamine. 
Both found an early decrease in intraocular pressure after ketamine administration 
with a return to awake values as the effect of the drug diminished.  The mean 
intraocular pressure dropped significantly in Badrinath et al’s study (35) but not in 
Peuler et al’s study (34), where changes although of a similar trend were smaller.  
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In a study by Ausinsch et al (36), despite 8mg/kg doses of ketamine intramuscularly, 
intraocular pressure under ketamine anaesthesia was found to be lower than 
measurements taken prior to induction.  Importantly, it was felt that ketamine did not 
lower intraocular pressure but rather eliminated the anxiety and lack of cooperation 
experienced in all but three of their awake patients. In phase II of this study the 
patients were given a further 1mg/kg bolus of ketamine intravenously 20 minutes 
after the initial intramuscular ketamine bolus.  This had no significant effect on the 
intraocular pressure compared to the values obtained at 20 minutes, confirming 
their hypothesis that ketamine reduced intraocular pressure through relief of anxiety 
rather than directly affecting intraocular pressure.  
In a trial by Halstead et al (37), baseline pressures were taken after drug 
administration, reducing the chance of finding a change in intraocular pressure. A 
study published by Drayna et al (38) observed a small, not clinically significant, 
elevation in intraocular pressure after administration of low doses of ketamine.  
Wadia et al (39) found only mild elevations in intraocular pressure with clinically 
significant elevations being transient. Since it has been shown that transient 
increases in intraocular pressure above 5mmHg in previously damaged eyes 
reduces ocular fundus pulsations and choroidal blood flow, it was felt that a clinically 
significant increase would need to be in this region. Of note, the patients who 
experienced higher increases in intraocular pressure were found to have lower 
baseline pain scores. This highlights a problem with using this population for 
studying the effect of ketamine on intraocular pressure, patients requiring 
procedural sedation are often anxious and in pain and thus any effect of ketamine 
could be masked by already elevated sympathetic stimulation during baseline 
intraocular pressure measurements. These studies have limitations which include 
the variety of procedures for which sedation is required, lack of control over the 
drugs given prior to sedation for analgesia and anxiolysis and lack of 
standardisation of other drugs administered. 
Nagdeve et al (40) suggested that the effect of ketamine was dose dependant. They 
found an increase in intraocular pressure when 6mg/kg of ketamine was 
administered but not when a lower dose was given. 
Blumberg et al (23) randomised 30 uncooperative paediatric patients with 
diagnosed or suspected glaucoma to undergo intraocular pressure measurement 
under either ketamine or sevoflurane anaesthesia. They found the mean intraocular 
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pressure at the first possible measurement to be significantly lower in those who 
received sevoflurane than that in the ketamine group.  There was also a significant 
sustained decline in intraocular pressure at each subsequent reading in the 
sevoflurane group.  After mathematical modelling was applied to both groups’ data it 
was shown that the true intraocular pressure was likely to have been the same as 
that measured in the ketamine group.   They concluded that intramuscular ketamine 
may provide more accurate readings of intraocular pressure than inhalational 
anaesthetics but that if sevoflurane is used intraocular pressure should be 
measured as soon as possible after induction in order to reduce the pressure 
lowering effects of sevoflurane on the measurements taken. As with many of the 
studies included here, limitations included a lack of awake measurements, a small 
sample size, the reliability of the readings taken using a TonoPen and that the 
investigators were not blinded.  
Jones et al (41) retrospectively looked at the effects of ketamine and sevoflurane in 
the same patients. Sixteen uncooperative children with glaucoma had intraocular 
pressure measured under ketamine anaesthesia and then again after sevoflurane 
had been administered. A 28.5% reduction in intraocular pressure was found after 
sevoflurane administration compared with initial ketamine readings. They felt that 
ketamine did not have a clinically meaningful effect on intraocular pressure and may 
be a better surrogate for awake intraocular pressure readings than sevoflurane. 
Studies evaluating the effects of sevoflurane or ketamine on intraocular pressure 
are summarized in Table C. 
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Table C: Summary of Trials on the Effect of General Anaesthetic Agents, Ketamine and Sevoflurane, on Intraocular Pressure 
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Some of the common additional drugs that are administered include glycopyrrolate 
or atropine, ondansetron, nitrous oxide, and opioids. 
Anticholinergic agents inhibit the muscarinic cholinergic receptors.  In the eye, the 
sphincter muscle of the iris and the ciliary body are both innervated by the 
parasympathetic nervous system via the oculomotor nerve. When this 
parasympathetic innervation is blocked, the sphincter muscle relaxes and the 
sympathetic innervation of the dilator papillae muscle is unopposed leading to 
dilatation of the pupil and potential obstruction of the drainage of aqueous humour 
leading to raised intraocular pressure.  Fortunately, in clinically used premedication 
doses these effects are not seen. In a study by Cozanitis neither glycopyrrolate nor 
atropine in clinically used doses were shown to increase intraocular pressure in 
healthy adult eyes.(45) 
Ondansetron, an antiemetic, has been shown not to increase intraocular pressure in 
adult patients requiring cataract surgery under general anaesthesia.(46) 
In 1985 Murphy (47) noted that the effect of nitrous oxide on intraocular pressure 
had received little attention despite its widespread use in anaesthetic techniques 
and its use in several of the studies documented above. This opinion still holds true.  
Besides its elevation of intraocular pressure when intravitreal gas is injected, little 
else is noted on nitrous oxide’s effect on intraocular pressure.  
Murphy (47) also concluded that intramuscular morphine reduces intraocular 
pressure in both those with and those without glaucoma. While it has been 
established that opioids would blunt a sympathetic surge to intubation which may 
increase intraocular pressure(48) as well as blunt sympathetic stimulation as a 
result of its analgesic properties, some studies have found intraocular opioid 
receptors which can directly reduce intraocular pressure.  In rabbits, intraocular 
injection of morphine resulted in an acute reduction in intraocular pressure – an 
effect which was prevented when conjunctival naloxone was administered.  Also, it 
has been found that conjunctival instillation of morphine in patients with chronic 
closed angle glaucoma reduces their intraocular pressure(49).  Studies on fentanyl 
and alfentanil show significant reductions in intraocular pressure(50) 
The variability of the anaesthetic technique between these studies challenge 
interpretation. This was highlighted by Al-Abrak  et al (51) when they studied the 
effect of halothane on intraocular pressure.  They highlighted standardisation of all 
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aspects of the anaesthetic in order to achieve reliable results.  This included the 
avoidance of premedications and depolarizing muscle relaxants, maintenance of 
constant intrathoracic pressure and central venous pressure through ventilator 
settings, a constant inspired oxygen concentration, maintenance of arterial pressure 
and supine positioning. 
 It is well established that airway manipulation particularly endotracheal intubation 
influences intraocular pressure(52). Whether or not a premedication is given, the 
dose given and the timing of the dose in relation to measurements can also 
influence outcomes.  Position of patient (53) and whether ventilation is controlled 
could also influence intraocular pressure (53, 54).  Lastly, outcomes of studies can 
be influenced by the technique used for measurement of intraocular pressure – the 
gold standard instrument would be a Goldman tonometer, this requires a sitting 
position and is thus unsuitable for use in theatre.  The technical experience of the 
person taking measurements as well as the number of investigators measuring 
pressures and whether they are blinded to the anaesthetic technique could 
influence the outcome. 
Deficits in current literature 
No single study evaluated the use of sevoflurane induction followed by intravenous 
ketamine infusion. The literature highlights the need for a standardised anaesthetic 
technique which includes guidelines on anaesthetic agents to be used, additional 
drugs to be given, the timing of intraocular pressure measurements, position of 
patient as well as guidelines for airway manipulation and ventilation control. 
It would appear that there are several confounding factors that make the literature 
difficult to interpret and the variability of the anaesthetic technique between the 
studies will also challenge interpretation. 
Few studies have looked at the particular population in which these findings are 
significant – those too young to cooperate with awake readings.  Also, it is not clear 
whether results from a population without glaucoma can be extrapolated to those 
who do have glaucoma.  The type of surgery that the study population is undergoing 
may influence results as well. For instance, patients in an emergency department 
requiring procedural sedation may have high levels of sympathetic stimulation due 
to recent injury which could influence the awake readings. 
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Particularly with regard to paediatric data we are often unable to obtain awake 
intraocular pressure measurements, precisely why an examination under 
anaesthesia is indicated. Recently, the trials where awake paediatric pressures 
have been taken have used older children, not the population which we need to 
study.  Some older studies took awake pressure readings, Corssen et al (31) 
omitted awake readings if the child was uncooperative, Yoshikawa et al (32) 
obtained readings after training patients prior to data collection and Ausinsch et al 
(25, 26, 36) used a heavy premedication regime, which may have interfered with  
intraocular pressure, in order to obtain awake measurements.  Most trials simply 
took baseline intraocular pressure readings as soon as possible after induction of 
anaesthesia.  While this may have impacted on the outcome of some trials, Adams 
(33) found that intraocular pressure increased after administration of ketamine but 
baseline pressures were measured under halothane anaesthesia. Other trials have 
attempted to eliminate this impact. Dominguez et al (28) repeated pressure 
measurements at 1 minute intervals until arousal and suggested measuring 
intraocular pressure just prior to arousal when Bispectral Index (BIS) indicates light 
anaesthesia. The interpretation of BIS in a paediatric context is not discussed here. 
In Blumberg et al’s trial (23) best fit regression lines for actual data were 
extrapolated backward in time to before induction. 
Contributions of this study 
Aileen Adams (33) said, ‘It would seem wise that any individual child should always 
be examined under the same anaesthetic agent if truly comparable readings are to 
be obtained’. We share goals in common with other authors on this subject.   
Dominguez et al (28) hoped to establish a general anaesthetic standard that would 
allow for repeated determinations of intraocular pressure in a quiet child.  They felt 
that such a protocol should be safe and reliable, and use drugs with little or no effect 
on intraocular pressure or at least with known effect on intraocular pressure. 
We aim to standardize the anaesthetic technique for intraocular pressure 
measurements in children with glaucoma presenting for examinations under 
anaesthesia at Red Cross War Memorial Children’s Hospital, to validate our 
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Abstract 
How does sevoflurane induction, followed by a ketamine maintenance infusion affect 
intraocular pressure? 
Establishment of a protocol for paediatric glaucoma examinations under anaesthesia. 
Purpose: 1.To determine the effect of sevoflurane induction, followed by 
intravenous (IV) ketamine infusion on intraocular pressure (IOP) in the paediatric 
glaucoma population.  2. To establish the earliest time point at which IOP 
measurement most closely resembles awake values.  
Methods: A prospective, descriptive study of the IOP changes occurring in 25 
children requiring IOP measurements at our institution. A standardised anaesthetic 
technique was employed; sevoflurane induction, intravenous cannulation, ketamine 
bolus (2mg/kg) and maintenance (4mg/kg/hr) for 15 minutes. IOP measurements 
and physiological variables were recorded after sevoflurane induction, then every 2 
minutes for a period of 10 minutes, one at 15 minutes as well as 5 minutes after 
ketamine discontinuation.   
Results: IOP was measured in 25 patients (50 eyes). Twenty-six eyes (52%) had 
glaucoma. The mean patient age was 29 months (range 2-88 months). The mean 
IOP after sevoflurane induction was 3,68mmHg lower than that with ketamine 
maintenance (sevoflurane eliminated) (95% CI 1,35 to 6,02mmHg) (p=0,002)). 
Physiological variables return to baseline at 8 minutes, which correlates with the 
time taken for sevoflurane to be eliminated from exhaled gas. The difference in IOP 
between ketamine anaesthesia (time 15 minutes) and near wakefulness was only 
0,28 mmHg (95% CI -2,23 to 2,79mmHg) (p=0,826). Mixed effects models showed 
similar trends but a higher baseline (7,85mmHg (6,19 to 9,51mmHg) (p<0,001)) in 
those with glaucoma when compared to those without.  
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Conclusion: Sevoflurane lowers IOP significantly when compared to ketamine 
anaesthesia. While eyes with glaucoma had a higher baseline than those which did 
not have glaucoma, both groups followed similar trends in response to the 
anaesthetic agents. This standardised anaesthetic protocol allows reliable IOP 
measurement 15 minutes after termination of sevoflurane and commencement of 
ketamine infusion, with no reported adverse events.  
Key Words: Intraocular Pressure, Paediatric, Glaucoma, Sevoflurane, Ketamine  
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Introduction 
Accurate measurement of intraocular pressure (IOP) is central to the management 
of paediatric glaucoma. Despite newer rebound technology techniques, many young 
children are uncooperative when attempting awake IOP measurements.  Squeezing 
of the eyelids as well as sympathetic surges from anxiety falsely raise intraocular 
pressure (1). Thus, young patients often require examination under anaesthesia 
(EUA) or sedation in order to obtain reliable readings. 
Most general anaesthetic agents appear to reduce intraocular pressure. These 
changes may be due to indirect mechanisms, reduction of arterial pressure, 
improved venous drainage and/or alteration of arterial blood chemistry (1). 
Anaesthetic agents can also interfere with central nervous system control of 
intraocular pressure (2).  More directly, anaesthetic agents can facilitate the 
production or drainage of aqueous humour or cause contraction or relaxation of the 
extraocular and orbicularis oculi muscles (2). Opioid receptors present within the 
eye influence intraocular pressure (3). In addition, practical aspects of anaesthesia 
such as endotracheal intubation and patient position can alter intraocular pressure 
(4). 
Sevoflurane progressively reduces intraocular pressure with prolonged duration of 
administration and increasing alveolar concentration (5). Reduction of intraocular 
pressure has also been seen with intravenous maintenance of anaesthesia using 
propofol (6). The effect of ketamine on intraocular pressure appears to be 
controversial. Early trials indicated that ketamine elevated intraocular pressure (7-9). 
These trials were criticised for measuring baseline pressures after drug 
administration and using larger doses of ketamine than usually used in clinical 
practice. Recent trials conclude that intraocular pressure measurements under 
ketamine anaesthesia are more likely to represent awake values than those 
measured under other forms of anaesthesia (10-13). 
At our institution, a quaternary paediatric hospital, the standard of care is an 
inhalational induction with sevoflurane, followed by intravenous cannulation. 
Intravenous cannulation can be challenging in young children, topical anaesthetic 
cream is not freely available and requires time to achieve good effect. Furthermore, 
the sympathetic stimulation caused by a difficult IV cannulation in an awake, 
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uncooperative child may itself elevate intraocular pressure. Even under the ideal 
conditions created by anaesthesia IV cannulation can be difficult. An ideal sedative 
for ophthalmic examinations, chloral hydrate (14), is not available at our institution. 
Concerns regarding midazolam sedation and intramuscular or oral ketamine are: the 
variability of systemic absorption, inability to titrate to clinical effect and the delay in 
onset of clinical effect. Prior to this study there was no standardised anaesthetic 
technique for glaucoma EUA’s and IOP measurement times were random at best. 
The primary aim of this prospective, observational study was to standardise the 
anaesthetic technique for the measurement of intraocular pressure, in order to 
obtain consistent effects with serial investigations.  The second aim was to establish 
the earliest time at which measurements could be made, that most closely reflect 
awake values. No other studies that the authors are currently aware of, have looked 
at the effects on intraocular pressure with the sequential use of sevoflurane 
induction followed by intravenous ketamine. 
Method 
The study was approved by the Human Research Ethics Committee (HREC ref 
459/2015). The study was conducted in accordance with the Declaration of Helsinki. 
Written informed consent was taken from each child’s parents or caregivers prior to 
commencement of the anaesthetic. 
Inclusion criteria were ASA 1-2 children under 36 months of age or those unable to 
cooperate for awake measurements, who required intraocular pressure 
measurement under anaesthesia. Exclusions included ASA 3 or 4 patients, patients 
with cardiac comorbidities, known difficult airways or any patient with a 
contraindication to the drugs used in the protocol.  
A standardised anaesthetic technique was introduced, with normal fasting guidelines 
and no premedication given. Pre-operative demographic data was recorded, 
including age (months), weight (kg), heart rate (beats per minute) and blood 
pressure (mmHg). Each patient’s ocular pathology was noted as well as any 
previous ophthalmic surgery that they had undergone. Anaesthesia was performed 
with two anaesthetists present, routine intraoperative monitoring and anaesthetic 
record keeping. 
A graded inhalational induction was performed, with sevoflurane increased to 6% in 
100% oxygen. This was done with a carefully applied facemask, avoiding pressure 
62 | D r  J e s s i c a  v a n  d e r  W a l t  – M M e d  D i s s e r t a t i o n
on the eyes, and an Ayre’s T-piece. Parents were present at induction. Once 
adequate depth of anaesthesia had been reached, assessed by the central position 
of patient’s eyes, an initial intraocular pressure measurement was obtained in each 
eye after instillation of lignocaine local anaesthetic eye drops.  All readings were 
taken by a single ophthalmologist using a Perkins applanation tonometer. Blood 
pressure, heart rate, end-tidal carbon dioxide concentration and sevoflurane were 
recorded at each measurement.  
Intravenous access was obtained, followed by a 2mg/kg bolus of ketamine and 
maintenance of a 4mg/kg/hr ketamine infusion (Alaris PK (CareFusion, South Africa) 
syringe driver by means of a 20ml BD plastic syringe (BD Medical-Pharmaceutical 
Systems, South Africa)). Sevoflurane was discontinued at the time of the initial 
ketamine bolus (time 0). Intraocular pressure and other vitals were then recorded 
every 2 minutes up until 10 minutes (times 2,4,6,8 and 10 minutes). Another 
measurement was taken at 15 minutes, at which point the ketamine infusion was 
discontinued and a final measurement was taken at 20 minutes, or earlier if the 
patient showed signs of emergence. 
Spontaneous ventilation was maintained throughout the procedure and 
supplementary oxygen supplied via nasal prongs, with end-tidal carbon dioxide and 
sevoflurane analysis.  
The administration of additional drugs or need for rescue airway management was 
documented. Where additional sedation was required an intravenous bolus of 1 
mg/kg ketamine was delivered. In the presence of excessive secretions, 10mcg/kg 
intravenous glycopyrrolate was administered at the anaesthetist’s discretion. 
Post-operative recovery and monitoring was performed according to the normal 
theatre recovery protocol and clinical practice. Recovery time and complications 
were documented. 
Statistical Methods: A sample size of up to 30 patients (60 eye evaluations) in this 
prospective observational study was regarded as likely to provide adequate 
statistical power, based on similar studies in literature. Data was captured in 
Microsoft Excel® and analysed using Statistica® (version 12.5).  Normally 
distributed demographic data was reported as mean, range and standard deviation. 
Categorical data was reported as counts and proportions. 
Generalized estimating equations described changes in IOP, heart rate and blood 
pressure and end tidal sevoflurane. Paired Student’s t-test was used if data was 
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normally distributed and a p-value of <0.05 was considered significant, as well as a 
Wilcoxon signed-rank test in the event of non-normal distribution.  
Results 
Demographics 
Data of 25 discrete examinations (50 eyes) was collected over a 25 month period 
from December 2013 to January 2015. Twenty-two patients were enrolled in the 
study. Three children required repeat examinations 5, 16 and 18 months apart. 
During this time 50 patients were scheduled for EUA, with 14% (7/50) not arriving 
and another 10% (5/50) cancelled on the day of surgery (Figure 1). 
n=50 Patients booked for EUA 
n=43 Eligible for enrolment 
n= 30 Consented 
 n=35 Eligible for enrolment 
n=25 Enrolled in Study 
7 Did not attend on day of surgery 
5 Exclusions: Cardiac Pathology 
5 Cancellations on admission: 
 4 sick on admission
 1 EUA no longer indicated
8 No investigators available 
Figure 1: Patients Excluded from Study
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Combination of data from left and right eyes was avoided as the physiological 
influences of one patient may have impacted on both eyes’ pressures. 
Table 1: Demographics of children included in study (n=25) 
 
Table 2: Presenting Pathology 
 
Table 3: Anaesthetic characteristics 
Characteristics Count SD Range 
Male: Female 14:11   
Age (months) 29 ±20 2-88 
Weight (kg) 12 ±4 5,8-21,5 
 Both 
eyes 
Right eye Left eye Neither eye Total 
Glaucoma 9 6 2 8 25 
Glaucoma 
Surgery 
6 3 3 13 25 
Cataract Surgery 11   14 25 
Characteristics Count SD Range 
Time to 1st IOPM (s) 319 ±110 150-525 
Time to achieve IV 
access(s) 
192 ±93 50-432 
Time to sevo washout(s) 420 ±120 240-600 
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Legend: IOPM: Intraocular pressure measurement; IV: Intravenous; Sevo: 
Sevoflurane 
The average time to achieve adequate depth of anaesthesia and first IOP 
measurement was 6 minutes. Fourteen patients (56%) received low dose ketamine 
(<4mg/kg) and 2 patients (8%) had a total ketamine dose > 6mg/kg. With the 
exception of one child, all additional ketamine boluses were required after 8 minutes 
(2 patients prior to 10 minute measurements, 5 patients (20%) after 10 minute 
measurements, and a further 2 patients at 15 minutes).  
A single patient required glycopyrrolate and airway intervention for increased 
secretions due to a recent upper respiratory tract infection. 
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Physiological Variables 
Physiological variables, heart rate (HR), systolic blood pressure(SBP) and mean 
blood pressure (MBP) were plotted along with intraocular pressure.(Figure 2) Blood 
pressure tends to drop after induction with sevoflurane (time 0) from preoperative 
values and then returns to preoperative levels 6 minutes after the sevoflurane has 
been discontinued. Similarly, heart rate increases after induction, and returns to 
preoperative values at 6 minutes. Heart rate values were not statistically different 
from preoperative values at 8 minutes (p=0,165). Similarly for systolic and mean 
blood pressure no statistical difference from preoperative pressures were found at 8 
minutes (pSBP=0,109 & pMBP=0,079 respectively).  
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End-tidal CO2 measurement with nasal 
cannula was achieved in 92% (23/25) of 
patients with a reading greater than 2 kPa. 
Sixty-eight percent (17/25) of patients 
consistently maintained an end-tidal CO2 ≥4 
kPa throughout the 20 minute observation 
period. No statistically significant difference 
was found between preoperative 
physiological values and sevoflurane 
‘washout time’ (7 ± 2 minutes). (Students’ 
paired t tests (pHR=0,2362; pSBP=0,0793; 
pMBP=1,0) (Wilcoxon – Rank tests 
pHR=0,2402; pSBP=0,1027; pMBP=0,8527)). 
Length of recovery period did not correlate with ketamine dose. Less than a third of 
the patients had a recovery room stay longer than 10 minutes (including those with 
>6mg/kg dose.) No child required overnight admission or had any side effects as a
consequence of this anaesthetic technique.
Intraocular Pressure Measurements 
Intraocular pressure measurements were performed in 50 eyes at stipulated time 
points (Figure 4).  More right eye measurements were affected by glaucoma (15/25) 
than left eyes (11/25) and the same number of left and right eyes had undergone 
glaucoma surgery. The mean intraocular pressures of eyes with glaucoma was 
higher than non-glaucomatous eyes, by 7,85 mmHg  (95% CI 6.19 to 
9.51)(p<0,001). Despite this, they seemed to follow similar pressure trends to non-
glaucomatous eyes. The confidence interval for the glaucoma group was wider than 
the non-glaucoma group implying more variability in intraocular pressure values 




















Figure 3: End-Tidal Sevoflurane and 
Carbon Dioxide over Time 
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Figure 4: IOP over time by glaucoma status 
Both the glaucoma and non-glaucoma mean intraocular pressures in the low dose 
ketamine group (<4 mg/kg) follow similar trends, with an elevation in baseline 
pressures in the glaucoma group. 
Comparing the intraocular pressure at time 0 (sevoflurane only) and time 15 minutes 
(ketamine alone, sevoflurane eliminated) showed a 3,68mmHg increase in average 
intraocular pressure. (95% Confidence Interval 1,35 to 6,02mmHg)  (p=0,002) 
Comparing time 15 minutes (ketamine only) and time 20 minutes (near wakefulness) 
there was a 0,28 mmHg difference between the average measured intraocular 
pressures (95% Confidence Interval -2.23mmHg to 2.79mmHg) (p=0,826)
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Discussion 
Paediatric glaucoma patients often require serial IOP measurements for optimal 
management. Al-Abrak et al (15) emphasised standardisation of all aspects of the 
anaesthetic in order to achieve reliable results.  
Awake IOP measurements are usually performed in older, cooperative children (11, 
12). Success rates with awake IOP measurements in young children are variable. 
Sihota et al (17) had a 50-60% success rate in determining awake IOP 
measurements in the 1-3 year age group (IOP measurements were taken in 405 
cooperative, unsedated children). A study by Oberacher-Velten et al (18) had only a 
14% success rate with awake IOP measurements in children aged  6 months to 2 
years. Ausinsch et al(19) used a heavy premedication regime in order to obtain 
awake measurements, while Corssen et al (9) omitted awake readings if the child 
was uncooperative. Shah et al (20) warn against measurement of intraocular 
pressure in awake paediatric patients even if they are cooperative. They attribute 
elevated intraocular pressure in cooperative paediatric patients to some unavoidable 
squeezing of the eyelids. 
Sedation would appear a feasible alternative but most general anaesthetic agents 
reduce intraocular pressure (2).  
Chloral hydrate sedation has been shown not to influence intraocular pressure(14) 
and has a sedation success rate of 93,7%(21). It was a feasible alternative for 
ophthalmologists in South Africa but has recently been withdrawn from the 
commercial market.  
Dexmedetomidine has been shown to reduce IOP (22-24). 
Midazolam’s effects on IOP have not been conclusively determined (18, 24-27). 
Most recently Shah et al (20) showed a significant reduction in intraocular pressure 
in cooperative patients after titration of midazolam to clinical effect. All opioids 
reduce intraocular pressure (2, 3, 28, 29). 
Young patients often require examination under anaesthesia (EUA) in order to 
obtain IOP measurements. Due to lack of uniformity between various trials and 
different population groups, interpretation of the available literature is challenging 
(Table 4). 
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Dominguez et al (5) showed a small but significant decrease in intraocular pressure 
when measured under the influence of sevoflurane (10% decrease at 2% 
sevoflurane concentration). Blumberg et al (13) showed that intraocular pressure 
was unchanged under ketamine anaesthesia while intraocular pressure showed 
significant decline with each subsequent pressure measurement taken under 
sevoflurane anaesthesia when they administered sevoflurane anaesthesia to half of 
the study population and ketamine anaesthesia to the other half. Jones et al’s 
results (16) were more substantial with a 28,5% reduction in intraocular pressure 
after administration of sevoflurane to children whose original pressure 
measurements were taken under ketamine anaesthesia. The children were induced 
with ketamine and sevoflurane was then added to maintain anaesthesia. No 
clinically significant changes in intraocular pressure have been found in recent 
paediatric trials where intravenous ketamine has been used for procedural sedation 
(10-12). 
The timing of IOP measurements may play a role. Most studies simply took baseline 
intraocular pressure readings as soon as possible after induction of anaesthesia.  
While this may have impacted on the outcome of some studies, Adams (8) found 
that intraocular pressure increased after administration of ketamine but baseline 
pressures were measured under halothane anaesthesia, other trials have attempted 
to eliminate this impact. Dominguez et al (5) repeated pressure measurements at 1 
minute intervals until emergence and suggested measuring intraocular pressure just 
prior to arousal when Bispectral Index (BIS) indicates light anaesthesia. The 
interpretation of BIS in a paediatric context is not discussed here. In a study by 
Blumberg et al (13), best fit regression lines for actual data was extrapolated 
backward in time to before induction.  
Our findings are in keeping with the pressure changes described in recent paediatric 
studies investigating the effects of ketamine and sevoflurane on intraocular pressure 
(13, 16). Our data showed a 3.68mmHg (95% CI 1,35 to 6,02mmHg) (p=0,002) 
increase in mean intraocular pressure when measured under the influence of 
ketamine alone, compared to intraocular pressure influenced by sevoflurane alone. 
This difference is greater than that attributed to diurnal variation. It emphasises the 
importance of taking intraocular pressure measurements under standardised 
anaesthetic regimes which include specification of the timing of such 
measurements. The much smaller difference in mean intraocular pressure when 
taken in patients under the influence of ketamine anaesthesia when compared to 
71 | D r  J e s s i c a  v a n  d e r  W a l t  – M M e d  D i s s e r t a t i o n
near awake values (0,28mmHg; 95% CI -2.23mmHg to 2.79mmHg) (p=0,826) 
suggests that measurements taken under the influence of ketamine anaesthesia are 
similar to those taken in awake patients. Overall, as expected, the readings appear 
lower when intraocular pressure is influenced by sevoflurane alone and gradually 
return to “awake’’ values as the sevoflurane is eliminated and ketamine is used to 
maintain anaesthesia.  
Drayna et al (11) suggested that intraocular pressure was not significantly 
influenced by ketamine if the dose was kept below 4mg/kg. Nagdeve et al (32) 
suggested that the effect of ketamine was dose dependant. They found an increase 
in intraocular pressure when 6mg/kg of ketamine was administered but not when a 
lower dose was given. Ninety-two percent of our patients had <6mg/kg total 
ketamine dose. In the 44% that required higher dose ketamine (>4mg/kg) we noted 
an elevated baseline IOP measurement prior to the administration of additional 
ketamine boluses. Therefore, the elevated intraocular pressures in this group cannot 
be explained by the higher ketamine dose alone. 
Eyes with glaucoma have higher baseline mean intraocular pressures than those 
without glaucoma but both groups followed similar trends in their response to the 
anaesthetic agents.  In keeping with our findings, several authors noted inconsistent 
changes in intraocular pressure in patients with glaucoma(8, 30). 
The timing of the readings remains important in obtaining results that reflect the 
awake state irrespective of whether the examined eye is diseased or not. 
Sevoflurane could no longer be detected in exhaled gas at 7,4 (SD +/-2,1) minutes, 
and the physiological variables, heart rate and blood pressure were not statistically 
different from preoperative values at 8 minutes. However, IOP still appears low at 
this point which suggests that it may still be under the influence of sevoflurane 
anaesthesia. In contrast, IOP at time 15 minutes closely resembles the near awake 
values (IOP difference 0,28mmHg; CI -2.23mmHg to 2.79mmHg) (p=0,826). We 
would thus recommend reading IOP 15 minutes after sevoflurane has been 
discontinued.  
Aileen Adams (8) said, ‘it would seem wise that any individual child should always 
be examined under the same anaesthetic agent if truly comparable readings are to 
be obtained.’  
This ideal was in keeping with Al-Abrak et al’s recommendations (15) to avoid 
premedications and depolarizing muscle relaxants, maintain constant intrathoracic 
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pressure and central venous pressure through ventilator settings and standardise 
patient positioning.  
The absence of awake IOP reference measurements and the small number of 
patients recruited are potential limitations of this study. Our sample size is larger 
than similar studies where statistically significant results were found (11, 13, 16).   
Our study reinforces the standardisation of anaesthetic technique, the measurement 
of intraocular pressure at predetermined time intervals by one ophthalmologist and 
the limited use of additional drugs which may have confounded the outcome. It adds 
to the current understanding of the effects of the anaesthetic agents on intraocular 
pressure. 
Conclusion 
Sevoflurane lowers IOP significantly when compared to ketamine anaesthesia. 
While eyes with glaucoma had a higher baseline than those which did not, both 
groups followed similar trends in response to the anaesthetic agents. This 
standardised anaesthetic protocol allows reliable IOP measurement 15 minutes after 
termination of sevoflurane and commencement of ketamine infusion with no 
reported adverse events.  
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Table 4: Summary of Paediatric Trials on the Effects of Anaesthetic Agents on Intraocular Pressure  
Study Year Age Patients Pathology Method 
 
Conclusion 
Corssen 1967 6 mths-77yrs 46 Normal IV Ketamine 1mg/lb 
 
Increase IOP 
Yoshikawa 1971 4-7 yrs 15 Normal IM ketamine 5mg/kg Transient increase IOP 
Adams 1973 3 mths-6 yrs 15 Normal vs 
Glaucoma 
 
IM Ketamine 10mg/kg Increase IOP 
Ausinsch 1975 1-17 yrs 28 No Glaucoma Halothane 1% / Isoflurane 1,5% Volitalie IOP similar to sedated  
 
Ausinsch 1976 2-10 yrs 10  Normal 8mg/kg IM Ketamine, then  
1mg/kg IV Ketamine/20 min 
 
Not increase IOP 





Halothane 1,5-3% in 50% N2O 30% Reduction in IOP 
Jaafar 1993 0-5 yrs 60 Normal vs 
Glaucoma 
 
Chloral hydrate 100mg/kg (10kg), then 50mg/kg  No change in IOP 
Blumberg 2006 1-216 mths 30 Glaucoma O2 + Sevo 8%  induction;  
Maintenance:Sevo(2-4%)vsKetamine IM(5-7mg/kg) 
 
IOP measured after ketamine represent 
awake IOP  
Nagdeve 2006 1-6 yrs 40 Normal IM Ketamine 6mg/kg vs 3 mg/kg Dose dependant effect on IOP,  
increased after 6mg/kg 
 
Dominguez 2009 3-10 yrs 30 Normal O2 + Sevoflurane 8% induction;  
40% N2O + Sevoflurane maintenance, titrated to BIS ≤ 50 
2% Sevo decrease IOP by 10%; 
Measurement of IOP:  
light anaesthesia(BIS),Sevo eliminated  
Jones 2010 26-89 mths 8 Glaucoma Induction: Ketamine IM(5mg/kg) vs IV(2mg/kg) 
Maintenance: 60% N2O + Sevoflurane 1,2%  





2011 15-72 mths 36 No effect  Midazolam (1mg/kg) premed. prior to GA Sedation doesn’t reduce IOP  
Drayna 2011 7-17 yrs 25 Normal Procedural sedation: IV Ketamine~1,88mg/kg  No increases in IOP 
 
Xu Lili 2012 3-7 yrs 60 Vitreoretinal Dexmedetomidine (0,5mcg/kg )IV infusion over 10 min vs 
placebo after Sevoflurane induction 
   
No reduction in IOP  
Halstead 2012 1-15 ys 80 Normal Procedural sedation: IV Ketamine~1,6mg/kg 
 
No increase in IOP 
Wadia 2014 8 -18 yrs 60 Normal Procedural sedation:IV Ketamine 0,5mg/kg/minute; Ave total 
dose 1,48mg/kg 
 
Mild increase in IOP  
(not clinically significant) 
Shah 2015 2-15 yrs 40 Strabismus IV Midazolam 0,1mg/kg bolus;  
0,05mg/kg midazolam/3 min. until spontaneous eyelid 
drooping (max 2,5mg/kg) 
 
Reduction in IOP  
(eyelid squeeze eliminated) 
 




All investigators participated actively in the planning and execution of this study. 
This included patient recruitment and consent, performance of anaesthesia and 
study technique, data capture and assessment. FR principal investigator, CT all IOP 
measurements, JvW wrote this manuscript and literature review. 
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Part D: Appendices 
Original Protocol 
Proposed protocol for Intraocular Pressure Measurement in children with 
glaucoma for examination under anaesthesia. 
Aim: 
To study the changes in intraocular pressure (IOP) and the correlation of the IOP 
curve over time, in patients with glaucoma who require examination under 
anaesthesia as a means to validate current practice at Red Cross Hospital.  
Inclusion criteria: 
Children with glaucoma 
Age 0-3 years 
Requiring EUA 
Day case surgery 
Exclusion criteria: 




Prospective observational study over 6 months or 30 patients. 
Children with glaucoma aged 0-3 years, who require intraocular pressure 
measurement under anaesthesia. 
Preoperative Demographic data [age (months), weight (kg), pulse, blood pressure] 
Standardised anaesthetic technique:  
normal fasting guidelines, clear fluids up to 2 hrs before surgery, 
milk/breastmilk >6hrs 
no premedication,  
routine intra operative monitoring & anaesthetic record keeping 
gas induction with Ayers T-piece, 100% oxygen  @ 5 l/min and Sevoflurane, 
gradual increase & limited to 6% until placement of intravenous cannula 
no topical local anaesthetics to eyes 
 maintenance of anaesthesia with : 
IV Ketamine bolus: 2 mg/kg followed by an infusion for 15 minutes 
IV Ketamine infusion: 4mg/kg/hr infusion 
(Alaris PK syringe driver with a 20ml BD plastic syringe) 
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should additional sedation be required a further bolus of iv  ketamine 
1 mg/kg 
Maintain spontaneous ventilation with nasal prong oxygen @ 4 l/min, 
and end tidal CO2 & Sevoflurane measurement. 
Alternative & rescue airway management on anaesthetist’s discretion 
Glycopyrrolate 10 mcg/kg for excessive secretion (on anaesthetist’s 
discretion) 
Should ongoing surgery be required, the anaesthetic technique employed should be 
at the discretion of the attending anaesthetist. 
Post-operative recovery and monitoring as per normal practice. 
Intra ocular pressure (IOP) measurements: 
Single operator 
IOP measurement both eyes, every time, irrespective of diseased/normal – 
10 sec/eye 
Perkins applanation tonometer is gold standard, calibrated prior to each 
measurement 
Anaesthetic data capture – 
 time to IV cannulation and first IOP measurement,
 total Sevoflurane administered, ( total dose, dose/kg ,dose/kg/min)
 total Ketamine administered, (total dose at each measurement time interval,
initial bolus, repeat boluses, total infused dose, total dose/kg)
 heart rate and  Blood pressure ( systolic, mean, diastolic) at every IOP
measurement intervals to compare with and see at which point it returns
preoperative heart rate and blood pressure baseline
 ? time interval to return of baseline heart rate and blood pressure
 Assessment postoperatively for any postoperative complications

IOP measurement intervals and data capture: 
 just prior to placing the intravenous (16) cannula with only sevoflurane on
board, no possible sympathetic effect of siting cannula or ketamine (time
0)
 1 minute after IVI cannulation with start of Ketamine anaesthesia and
discontinuation of Sevoflurane anaesthetic.
 every 2 minutes thereafter
 At 15 minutes after IV cannulation the Ketamine infusion is stopped and
final measurement is taken at 20 minutes.
Thus IOPM @ 0, 1,3,5,7,9,11,13,15,20 min 
Consent 
Informed consent of parent / guardian of child with glaucoma presenting for IOPM 
EUA to be included into the study and to perform IOPM. 
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Background: 
Integral to the management of glaucoma is the accurate measurement of intraocular 
pressure. For accurate IOP measurement in very young children less than 3 years 
of age examination under general anaesthesia (EUA) is required because they don’t 
tolerate awake IOP measurements. 
There are studies reflecting the effects of ketamine induction (intramuscular) 
followed by sevoflurane, sevoflurane vs ketamine, ketamine alone and halothane 
with ketamine but no studies have looked at the effects on IOP of sevoflurane 
induction followed by ketamine sedation. 
It is well known that most anaesthetics agents used for EUA may affect the IOP. 
Sevoflurane may decrease the IOP, and ketamine may increase the IOP. It is 
claimed that IOP is unaffected directly after induction of anaesthesia and that 
Ketamine less than 4 mg/kg doesn’t have a clinical meaningful elevation in IOP. 
At Red Cross Children’s Hospital it is currently our practice to induce anaesthesia 
with a sevoflurane gas induction followed by Ketamine sedation, but there are 
several variations to this technique and IOP measurements have been at random 
time intervals.  
We would like to validate our current practice and follow the changes of the 
intraocular pressure with a standardised anaesthetic technique and evaluate the 
correlation of the IOP curve over time to aid clinical practice, optimal measurements 
Dr F Roodt  – Anaesthetic consultant 
Dr C Tinley  – Paediatric Ophthalmologist 
Dr Jessica van der Walt – Anaesthetic registrar 
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Synopsis 
Synopsis of the proposed study of: 
Intraocular Pressure Measurement in children with glaucoma for examination under 
anaesthesia 
Introduction: 
Integral to the management of glaucoma is the accurate measurement of intraocular 
pressure (IOP). For accurate IOP measurement in very young children less than 3 
years of age examination under general anaesthesia (EUA) is required because 
they don’t cooperate nor tolerate awake IOP measurements. 
There are studies reflecting the effects of intramuscular ketamine induction followed 
by sevoflurane, sevoflurane vs ketamine, ketamine alone and halothane with 
ketamine for EUA’s. Propofol sedation is another possibility, but would also 
potentially decrease IOP, may suppresses airway reflexes and is not widely used in 
very small children. Dexmedetomidine is an attractive alternative, but its use in 
paediatric anaesthesia is currently off licence and may be a consideration for a 
future study. 
It is well known that most anaesthetic agents used for EUA may affect the IOP. 
Sevoflurane may decrease the IOP, and ketamine may increase the IOP. The 
intraocular effects of ketamine have recently been contested. It is claimed that IOP 
is unaffected directly after induction of anaesthesia and that Ketamine less than 4 
mg/kg doesn’t have a clinical meaningful elevation in IOP.  
Review of recent literature: 
1. 2010 Jones et al – studied 8 patients (16 eyes) to show a statistically significant
difference in intraocular pressure when ketamine was used for induction followed
sevoflurane for maintenance of anaesthesia, with remeasurement of intraocular
pressure.
2. 2011 Drayna et al - measured intraocular pressures in 25 older children with
normal eye pressures before and after ketamine - and found no statistical difference
in the eye pressures before and after ketamine, concluding that low dose ketamine
does not affect intraocular pressure.
3. 2006 Blumberg et al - divided 30 eyes into 2 groups and administered ketamine
to one group and sevoflurane to the other and showed that ketamine was more
representative of awake intraocular pressures than sevoflurane.
No studies have looked at the effects on IOP of sevoflurane induction followed by 
ketamine sedation as is currently our practice at Red Cross Children’s Hospital and 
the dilemma at which point the IOP during the EUA best reflect the awake IOP.   
Aims: 
To study the changes in intraocular pressure (IOP) and the correlation of the IOP 
curve over time, in patients with glaucoma who require examination under 
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anaesthesia(EUA) as a means to validate current practice at Red Cross Hospital, 
with a standardized anaesthetic technique 
Methods: 
We propose a prospective observational study over 6 months or 30 patients, in 
children with glaucoma aged 0-36 months, who require intraocular pressure 
measurement under anaesthesia. We have derived at 30 patients (60 eye 
evaluations) as guided by literature review and in consultation with a statistician. We 
do approximately 5 such cases/ month and as such the study should take 6 month 
to be completed. 
At Red Cross Children’s Hospital it is currently our practice to induce anaesthesia 
with a Sevoflurane gas induction followed by Ketamine sedation, but there are 
several variations to this technique and IOP measurements have been at random 
time intervals.  
To determine the optimal time to measure IOP in paediatric glaucoma patients 
during EUA, we would like to audit and validate our current practice, with a 
standardized anaesthetic technique with frequent measurement of the intraocular 
pressure to best determine when these measurements should be made in daily 
practice. 
The proposed study will lengthen the EUA anaesthetic time by 5-10 minutes 
compared to standard practice and would allow for 8 intraocular measurements per 
eye. Standard practice is 2-3 subsequent measurements per eye. 
The standardized anaesthetic technique and measurements of intraocular pressure 
are set out in the proposed protocol.  
Data to be collected include preoperative demographical data (age, weight, pulse 
and blood pressure), ophthalmic data (normal/affected eyes, intraocular pressure) 
and anaesthetic data (total ketamine and sevoflurane used, end tidal gasses- CO2 
& sevoflurane, blood pressure, pulse, variations in anaesthetic technique, recovery 
time and any complications). 
Patient’s safety is paramount and as such there will be two anaesthetists dedicated 
to the list. The attending anaesthetist performs the anaesthesia with routine 
anaesthetic care, intra-operative monitoring and record keeping. The 
ophthalmologist performs the intraocular pressure measurements while the second 
anaesthetist is the investigator to record the study data.  
In the event that further on going surgery are required at the end of the EUA period, 
the anaesthetic technique to be employed is left up to the discretion of the attending 
anaesthetist. 
Post-operative recovery and monitoring will be as per normal standard of care and 
practice. 
Inclusion criteria: 
Children with glaucoma 
Age 0-3 years 
Requiring EUA 
Day case surgery 
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Exclusion criteria: 
Contra indication to Sevoflurane / Ketamine anaesthesia 
Difficult airway 
ASA 3-4 
Most of the proposed Protocol/Study conforms to standard practice of care. 
Patient consent 
Consent for this study should be no different than normal informed consent obtained 
preoperatively by the surgeon from the parent/ guardian of the patient who presents 
with glaucoma for EUA. 
The difference of the protocol from standard practice are as follows; implementation 
of a standardized anaesthetic technique and a more frequent IOP measurements – 
both of which will be explained at time of consent for the procedure. 
Additionally verbal and written information about the audit of current clinical practice 
will be given to the parent/ guardian with written consent to use the ophthalmic and 
anaesthetic data collected for possible research, presentation and publication 
purposes. This is available in Afrikaans, English and Xhosa. The written information 
sheet is given to the parent and the consent is attached to normal procedural 
consent form. 
Cost and consumables 
No special equipment or consumables are required. All equipment stipulated in the 
protocol is available in theatre and is used on a daily basis as part of routine 
anaesthetic practice. 
No conflict of interests to declare, and no sponsorship from trade. 
Attached are the following: 
Proposed Protocol and application form FSHO13 
Appendices A: patient information sheet and consent to use the data (A1-
A3) 
Appendices B: Patient data sheet 
To be kept in the anaesthetic consultant’s office in the 
Anaesthetic department. No patient information will be 
disclosed and no data will be linked to the patient details or 
will be included in any presentations of the audit material. 
Appendices C: Anaesthetic and ophthalmic Audit data sheet, 
Used for data collection and analysis. 
Regards 
The investigators: 
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Dr F Roodt  – Anaesthetic consultant, email: francois.roodt@gmail.com 
Dr C Tinley  – Paediatric Ophthalmologist, email: Christopher.Tinley@uct.ac.za 
Dr Jessica van der Walt – Anaesthetic registrar, email: 
jessicagwendoline@hotmail.com 
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Research Application Form 
Form FHS013: New protocol application form – section A 
Researchers must ensure that they use the current version of the application form on 
the Administrative Forms web page
1. General information
Protocol number (if 
applicable) & Protocol 
title
To study the changes in intraocular pressure (IOP) and the 
correlation of the IOP curve over time, in patients with 
glaucoma who require examination under anaesthesia as a 
means to validate current practice at Red Cross Hospital 
2. Investigator(s) profile
UCT’s principal investigator (PI) 
Title, first name, surname Dr Fancois Roodt 
Department/Division Department of Anaesthesia 
Phone 0214045001 
Email address francois.roodt@gmail.com 
Office Internal Mail Address D23 Department of Anaesthesia 
Registration with HPCSA (tick √) x  Yes   No Registration # Mp0533823 
Note: 
 If a non-medically trained PI is overseeing research which involves medical
procedures, the application must include a medical doctor registered with the
HPCSA as a co-investigator.
 The research must have a UCT-based principal investigator, co-investigator or
supervisor.
2.2 Co-investigator(s) 
Title, first name, surname Department/Division E-mail
Dr Christopher Tinley Peadiatric 
Opthalmology
Christopher.Tinley@uct.ac.za 
Dr Jessica van der Walt Anaesthetic Registrar jessicagwendoline@hotmail.com 
2.3 How many of the following does the PI currently oversee? 
(Total number for all research projects) 
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Open research studies 0 Sites (excluding this application) 0 
Co-investigators 0 Number of participants 0 
 
 
2.4 What is the PI’s role in authoring this protocol?  (tick √) 
Primary author x 
Collaborator  
None (developed by sponsors)  
 
2.5 Are there any publication restrictions on the research? 
x  No   Yes 
If yes, please describe and justify: 
- 
 
3. Protocol profile 
3.1 Has this protocol been submitted to another Human Research Ethics Committee? 
(tick √) 










3.2 To your knowledge, has this protocol been rejected by another HREC? (tick √) 
x  No   Don’t know   Yes 
If yes, please provide the reasons: 
- 
 
3.3 Is this application similar or related to research previously approved by this 
Committee? (e.g. a sub-study, follow-up study, earlier phase trial)? (tick √) 









3.4 Is this protocol for degree purposes? (tick √) 
  No x Yes 
If yes, please specify: 
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Type of degree MMed 
Student’s name and e-
mail
Dr Jessica van der Walt, jessicagwendoline@hotmail.com 
Supervisor’s name and 
e-mail
Dr Francois Roodt, francois.roodt@gmail.com 
Department and 
University 
Department of Anaesthesia - UCT 
3.5 Does this protocol comply with the Helsinki Declaration of 2008? (tick √) 
  No x  Yes 
If no, please explain with full justification 
3.6 Does the protocol provide insurance for research-related adverse events (tick √) 
  NA (e.g. minimal risk research, medical record review) x  
No
  Yes 
If yes, please describe: 
ABPI-compliant corporate insurance policy 
UCT’s no-fault insurance policy 
Other. Please specify 
3.7 Does the protocol comply with UCT’s intellectual property rights policy? (tick √) 
x  Yes   No 
If no, please justify 
4. Funding and grant information    (No funding/sponsor  skip to Q. 5)
4.1  Funding source (tick √ at 
least one)   
Ethics Review 
Levy – cost 
including vat 
UCT (e.g. departmental funding) R0 
Grant Funding Organizations (e.g. MRC, NRF, CANSA,) R0 
Federally funded / Foundation sponsored / Private 
Institutions (BELOW R1m) 
R5 700 
Federally funded / Foundation sponsored / Private 
Institutions (ABOVE R1m) 
R11 400 
89 | D r  J e s s i c a  v a n  d e r  W a l t  – M M e d  D i s s e r t a t i o n
Pharmaceutical / Industry Driven company sponsors an 
investigator to conduct a new research project 
R22 800 
Pharmaceutical / Industry Driven Additional Clinical Site / 
Extension study 
R11 400 
Note: the HREC does not have the authority to waiver the ethics review levy. If a waiver is 
required, please contact Mr Salie Nassiep, the Research Management Accountant in the 
Faculty of Health Sciences (021 406 6409) email: salie.nassiep@uct.ac.za 
4.2 What is the total sponsorship/funding for this 
protocol?  
4.3 Into what entity will the funding be paid? 
4.4 Ethics review levy (Clinical & Industry-sponsored research only) 





4.5 Where applicable, has the PI negotiated an agreement with the hospital or other 
health or laboratory services to cover the costs of interventions/ procedures/ 
investigations performed solely for research purposes? (e.g. extra MRIs, CT scans, diagnostic
tests, prolonged hospitalisation, use of non-research staff to collect research-related data or perform research-
related procedures) (tick √) 
  NA   Yes   No 
If no, please explain how research costs will be recovered 
Note: a summary budget must be attached in the appendices. 
5. Characteristics of the protocol
5.1 Category of research 
Please select an appropriate category for your protocol. If the protocol falls in more than one 
category, please designate a primary and secondary category by entering a ‘1’ and a ‘2’. 
Medical intervention/ clinical trial (e.g. drugs, devices, innovations) 
Behavioural/ psychosocial interventions (e.g. comparison of counselling 
programmes) Epidemiology/ observational study (e.g. survey, prevalence, case control, cohort
studies) 
1 
Quality improvement 2 
Testing new technologies 
Medical record review, audit 
Establishment of a specimen repository, medical data base/ registry 
Clinical laboratory studies 
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Clinical laboratory studies (DNA related)  
Qualitative research (e.g. focus groups, in-depth interviewing, ethnography)  
Pilot study  
Other. Please describe:  
 




x  Minors (<18 years). Please specify age range: 0-3 
years  









5.5 Location(s) of the study: 
Red Cross Children’s Hospital – ophthalmic theatre 
 
 
5.6 Will non-English speaking participants be enrolled in the study? (tick √) 
  NA   No x  Yes 
 
If yes, please tick √ what measures will be used to promote participants’ and families’ 
understanding: 
Written translation of consent/ assent forms into Afrikaans  
Written translation of consent/ assent forms into Xhosa  
Use of trained translator(s)/ interpreter(s)  
Other. Please specify below and describe how the investigators intend to explain the study 







5.7 What measures will be taken to protect confidentiality (tick √) 
Paper-based records will be kept in a secure location and only accessible to 
personnel involved in the study 
x 
Computer-based records will only be available to personnel involved in the study 
through the use of access privileges and passwords 
x 
Personnel will be required to sign statements agreeing to protect the security 
and confidentiality of identifiable information 
 
Personal identifiers will be removed from research-related information x 
Encryption  
Audio and/ or video recordings will be transcribed and then destroyed to 
eliminate identification of participants 
 
Use of pseudonyms  
Participants in focus groups will be advised that confidentiality cannot be 
assured 
 




This section must be completed only if the research involves a clinical trial of drugs/ 
medicines, herbal, complementary or indigenous therapies; therapeutic devices; an 
innovative therapy or intervention; off-label use or a departure from standard treatment or 
care. 
The SA GCP Guidelines (2006) define a clinical trial as any investigation in human participants intended to discover 
or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product(s), and/or 
to identify any adverse reactions to an investigational product(s) and/or to study absorption, distribution, metabolism 
and excretion of an investigational product(s) with the objective of ascertaining its safety and/or efficacy. 
Is this protocol a clinical trial (tick √):   Yes x  No  (If no, please go to 
Q.7) 
6.1 Is the product registered with the 
Medicines     Control Council (MCC)? (tick √) 
  Yes  No
If yes, please provide the registration number 
If no, is the MCC’s letter for use of an 
unregistered medicine attached? 
 Yes 
 No 
 Application submitted 
If registered, will the product be studied for an indication different to 
that approved in the SA package insert? 
  Yes   No 
If registered, will the product be studied using a dose different to that 
approved in the SA package insert? 
  Yes   No 
If registered, will the product be studied using a formulation different to 
that approved in the SA package insert? 
  Yes   No 
If registered, will the product be studied using a route of 
administration different to that approved in the SA package insert? 
  Yes   No 
Note:  If yes to any of the above, MCC approval is required. 
6.2 Does the study involve an FDA-monitored 
product (drug, device or biological)? (tick √) 
  Yes   No 
6.3 Is this trial registered with the South 
African Clinical Trial Register? 
  Yes   No  
If yes, please provide the registration number 
If no   Application submitted 
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6.4 Does this trial comply with the Guidelines 
for Good Practice in the Conduct of Clinical 
Trials with Human Participants in South 
Africa, 2nd Edition, 2006? (tick √): 
  Yes   No  
If no, please justify 
6.5 Is the PI covered by professional liability 
insurance? (tick √): 
  Yes   No  
If yes, please provide Medical Protection number 
6.6 Trial design (tick √ all that apply) 
 Placebo-
control 
Please justify use of a placebo: 
 Phase I  Phase II  Phase III 
 Phase IV  
 Single centre  National multi-centre  International 
multi-centre 
 Open label/ roll-over/ extension study. (If yes, a summary of the main findings, including 
safety and efficacy data, from the previous study must be included in the appendices. This is 
a requirement for HREC review.) 
6.7 Is the PI free to publish the findings of 
this trial?  (tick √) 
  Yes   No  
If no, please describe the conditions of 
publication. 
7. Statement of conflict of interest
The PI is expected to declare any existing or potential conflict of interest that may affect the 
scientific integrity and ethical conduct of this research. For purposes of this section, 
‘immediate family’ means the PI’s spouse or domestic partner and dependent children.  
Please tick √ all that apply:
I, or any member of my immediate family, do not have any interest related to this 
research (e.g. financial interest in the sponsor of the research or intervention 
being tested.) 
x 
I, or any member of my immediate family, do not have a proprietary interest in 
the product being tested in this research (e.g. patent, trademark, copyright, 
licensing agreement). 
x 
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I, or any member of my immediate family, do not have any relationships related 
to this research (e.g. board membership, consultative, executive, employment) 
or any entity with an ownership interest in the research other than the 
relationship of sponsor-investigator. 
x 
As Principal Investigator of this research I am aware of a potential conflict of 
interest. Please describe and provide a plan to manage the conflict of interest in 
the space below: 
none 
8. Declarations and Signatures
This application will not be processed unless all the required declarations and signatures are 
completed according to the Committee’s Standard Operating Procedures. 
8.1 Head of Department or Division 
 
My signature confirms that: 
i. The researcher(s)/student(s)/supervisor(s) have the skills, training, experience and time
to undertake this research.
ii. There are adequate resources (e.g. equipment, space, support services) to perform this
research.
Signature of Head Date 
Print name 
Note: Where the PI is also Head of Department, confirmation must be obtained from an 
authorised designee. PIs may not approve their own research. 
8.2 Chairperson of the Departmental Research Committee (DRC) 
My signature confirms that: 
i. This research has undergone peer review by a person(s) experienced in the field of
study.
ii. This research is well-designed and scientifically sound.
iii. Where relevant, all methodological issues have been resolved to the satisfaction of the
peer reviewer(s).
iv. If conducted according to the protocol, this research is expected to yield valid and




Note: Where the PI is also the Chairperson of the DRC, confirmation must be obtained from 
an authorised designee. PIs may not approve their own research. 
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8.3 Student supervisor  (if research is for a degree) 
My signature confirms that: 
i. The student researcher has adequate training and resources to complete the research
in the allocated timeframe.
ii. The research has scholarly merit.
iii. The level of risk inherent in the study is commensurate with the student researcher’s
experience and the extent of oversight that I will provide.
iv. I will meet the student on a regular basis to monitor progress and address any
problems that may arise during the study.
v. If applicable, I will ensure that the research undergoes continuing review as required by
the HREC.
vi. If applicable, I will ensure that the student researcher reports unanticipated problems or
serious adverse events to the HREC.
vii. I will arrange for an alternative faculty supervisor to take responsibility for this research




Print name Francois Roodt 
Note: The supervisor and student researcher are jointly responsible for the ethical conduct 
of this research from inception to dissemination of findings. 
8.4 Principal investigator 
My signature confirms that: 
i. Information in this application is true and accurate.
ii. I will begin the research only after HREC approval is obtained.
iii. I accept full responsibility for the conduct of this research and the protection of
participants’ rights and welfare.
iv. I will conduct the research according to all ethical, regulatory and legal requirements
laid down in the HREC’s Standard Operating Procedures.
v. I will provide progress reports to the HREC as requested, including a final closing report
at the end of the research.
vi. I will notify the HREC in writing if any change to the research is proposed and await
approval before proceeding with the proposed change except when urgently necessary
to protect participants’ safety.
vii. I will notify the HREC in writing immediately if any adverse event or unanticipated
problem occurs during the research.
viii. I will allow an audit of my research if requested by the HREC.
ix. I have the time, training, experience and resources to oversee this research.
Signature of PI Date: 1/7/2012 
Print name Francois Roodt 
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New protocol submission checklist
Please ensure that all the applicable sections are fully completed and included in the 
submission. Missing information will delay the review process as the application will be 
returned to the PI. Sections A-C must be included. Instructions for submission of new 
applications are posted on the HREC website.
Have you included? 




x Section A: New Protocol Application Form 3 2
x Section B: Synopsis 35 2
x Section C: Research Protocol 3 2
□ Appendices (as applicable): 3 
□ Sponsor’s protocol 3 2
□ NIH or other US federal grant application (if PI is primary awardee) 3 1
□ Investigator’s brochure and package inserts 3 NA
□ Surveys, questionnaires, interview schedules 3 2
□ Recruitment materials: advertisements, flyers, posters 3 2
□ Materials for participants: diaries, patient identification cards 3 2
□ Consent and assent forms (English versions) 35 2
□ Letters of authorisation from institutions such as hospitals, clinics
and schools 3 2
□ A summary of Phase III efficacy and safety data if this is an
application for an open label or extension study 3 NA
□ Budget summary 3 2
□ MCC letter of approval, if available 3 NA
□ If an application has been submitted to the MCC, a copy of Section
13 (Ethical Issues) extracted from the CTF1 application form 3 NA
□ In the case of clinical trials, PI’s declaration, CVs and GCP
certificates for PI and co-investigators
□ Other relevant documentation
Please submit the 
completed protocol 
together with an 
electronic copy to: 
Mrs Lamees Emjedi 
Research Ethics Committee 
E 52 Room 24, Old Main Building, Groote Schuur Hospital, 
Observatory 
Telephone:  27 21 406 6338 
Fax: 27 21 406 6411 
Email: nosi.tsama@uct.ac.za and 
shuretta.thomas@uct.ac.za 
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Human Research Ethics Committee – Study Approval 
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Human Research Ethics Committee - Renewal
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Human Research Ethics Committee - Amendment 
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Dear Parent / Guardian 
Your child with glaucoma is scheduled for an examination under anaesthesia with regard to his medical 
condition.  In order to improve services at Red Cross Hospital, we are auditing current anaesthetic practise for 
children who have glaucoma. 
At present, we put these patients to sleep using Sevoflurane anaesthetic gas, we insert an intravenous line 
(drip) into the child when he or she is asleep and then turn the anaesthetic gas off, keeping the child asleep 
with an intravenous drug called Ketamine.  We then take three intraocular pressure measurements on the 
patient and then wake him or her up again.  We know that both the anaesthetic gasses and our intravenous 
drugs can have an effect on the pressure within the patient’s eyes and thus would like to take a few more 
readings in order to establish more clearly how much effect these drugs are having on our measurements and 
at what stage we are achieving the most accurate results. We will thus take eight measurements of intraocular 
pressure as opposed to the usual three readings.  This will mean that your child’s anaesthetic will last five to ten 
minutes longer than a routine examination. 
As always we will strive to deliver a safe anaesthetic to your child with no deviation from our standard care. 
We request your permission to use the data we collect in our research and possibly in publications at a later 
stage.  No personal information will be used in this research that would allow your child to be personally 
identified. 
We thank you for your cooperation in allowing us to improve our standard of care to children with glaucoma. 
Should you have any queries please feel free to contact one of our researchers. 
Regards 
Chris Tinley 
Francois Roodt 079 679 1030 
Jessica van der Walt 082 348 6566 
 
Human Research Ethics Committee  
Reference number 459/2012 
Contact number 021 406 6338 
 
 
I ----------------------- give permission for my child’s data to be used as part of an audit of anaesthetic 
management during intraocular pressure measurements. 
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Data Capture Form 
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Patient Data Form 
Study 
no. Date Patient Sticker Diagnosis 
1 
      
2 
      
3 
      
4 
      
5 
      
6 
      
7 
      
8 
      
9       
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Journal of Glaucoma – Author Instructions 
8/13/2015 Editorial Manager Journal 
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http://edmgr.ovid.com/jog/accounts/ifauth.htm 1/7 
Journal of Glaucoma 
Online Submission and Review 
System 
SCOPE 
The Journal of Glaucoma is a peer reviewed 
journal addressing the spectrum of issues 
affecting definition, diagnosis, and 
management of glaucoma and providing a 
forum for lively and stimulating discussion of 
clinical, scientific, and socioeconomic factors 
affecting care of glaucoma patients. 
Instructions for Authors (this page) 





Ethical/Legal Considerations. A submitted manuscript must be an original contribution not 
previously published (except as an abstract or preliminary report), must not be under 
consideration for publication elsewhere, and if accepted, it must not be published elsewhere in 
similar form, in any language, without the consent of Lippincott Williams & Wilkins. Each 
person 
listed as an author is expected to have participated in the study to a significant extent. 
Although 
the editors and referees make every effort to ensure the validity of published manuscripts, the 
final responsibility rests with the authors, not with the Journal, its editors, or the publisher. All 
manuscripts must be submitted online through the journal's electronic submission 
site www.editorialmanager.com/jog See submission instructions under "Online manuscript 
submission." 
FINANCIAL DISCLOSURE: Each author warrants that he or she has no commercial 
associations (e.g., consultancies, stock ownership, equity interest, patent/licensing 
arrangements, etc.) that might pose a conflict of interest in connection with the submitted 
article, except as disclosed on a separate attachment. All funding sources supporting the Work 
and all institutional or corporate affiliations of the authors are acknowledged in a footnote in 
the 
Work and on the Copyright/Financial Disclosure form that is requested upon acceptance. 
Patient Anonymity and Informed Consent 
It is the author's responsibility to ensure that a patient's anonymity be carefully protected and 
to 
verify that any experimental investigation with human subjects reported in the manuscript was 
performed with informed consent and following all the guidelines for experimental investigation 
with human subjects required by the institution(s) with which all the authors are affiliated. 
Authors should mask patients' eyes and remove patients' names from figures unless they 
obtain 
written consent from the patients and submit written consent with the manuscript. 
Open access 
LWW's hybrid open access option is offered to authors whose articles have been accepted for 
publication. With this choice, articles are made freely available online immediately upon 
publication. Authors may take advantage of the open access option at the point of acceptance 
to 
ensure that this choice has no influence on the peer review and acceptance process. These 
articles are subject to the journal's standard peerreview 
process and will be accepted or rejected 
based on their own merit. 
Authors of accepted peerreviewed 
articles have the choice to pay a fee to allow perpetual 
unrestricted online access to their published article to readers globally, immediately upon 
publication. The article processing charge for Journal of Glaucoma is $2,500. The article 
processing charge for authors funded by the Research Councils UK (RCUK) is $3,175. The 
publication fee is charged on acceptance of the article and should be paid within 30 days by 
credit 
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card by the author, funding agency or institution. Payment must be received in full for the 
article 
to be published open access. 
Authors retain copyright 
Authors retain their copyright for all articles they opt to publish open access. Authors grant 
LWW a license to publish the article and identify itself as the original publisher. 
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Creative Commons license 
Articles opting for open access will be freely available to read, download and share from the 
time of publication. Articles are published under the terms of the Creative Commons License 
AttributionNonCommerical 
No Derivative 3.0 which allows readers to disseminate and reuse 
the article, as well as share and reuse of the scientific material. It does not permit commercial 
exploitation or the creation of derivative works without specific permission. To view a copy of 
this license visit: http://creativecommons.org/licenses/byncnd/ 
3.0. 
Compliance with NIH, RCUK, Wellcome Trust and other research funding agency 
accessibility requirements 
A number of research funding agencies now require or request authors to submit the postprint 
(the article after peer review and acceptance but not the final published article) to a 
repository that is accessible online by all without charge. As a service to our authors, LWW 
identifies to the National Library of Medicine (NLM) articles that require deposit and transmits 
the postprint 
of an article based on research funded in whole or in part by the National 
Institutes of Health, Howard Hughes Medical Institute, or other funding agencies to PubMed 
Central. The revised Copyright Transfer Agreement provides the mechanism. LWW ensures 
that authors can fully comply with the public access requirements of major funding bodies 
worldwide. Additionally, all authors who choose the open access option will have their final 
published article deposited into PubMed Central. 
RCUK and Wellcome funded authors can choose to publish their paper as open access with 
the payment of an article process charge (gold route), or opt for their accepted manuscript to 
be deposited (green route) into PMC with an embargo. 
With both the gold and green open access options, the author will continue to sign the 
Copyright Transfer Agreement (CTA) as it provides the mechanism for LWW to ensure that 
the author is fully compliant with the requirements. After signature of the CTA, the author 
will then sign a License to Publish where they will then own the copyright. Those authors 
who wish to publish their article via the gold route will be able to publish under the terms of 
the Attribution 3.0 (CCBY) License. To view of a copy of this license visit: 
http://creativecommons.org/licenses/by/2.0/. Those authors who wish to publish their article 
via the green route will be able to publish under the rights of the Attribution Noncommercial 
3.0 (CCBY NC) license (http://creativecommons.org/licenses/bync/ 
2.0/). 
It is the responsibility of the author to inform the Editorial Office and/or LWW that they have 
RCUK funding. LWW will not be held responsible for retroactive deposits to PMC if the author 
has not completed the proper forms. 




Authors must submit written permission from the copyright owner (usually the publisher) to 
use 
direct quotations, tables, or illustrations that have appeared in copyrighted form elsewhere, 
along 
with complete details about the source. Any permissions fees that might be required by the 
copyright owner are the responsibility of the authors requesting use of the borrowed material, 
not the responsibility of Lippincott Williams & Wilkins. 
Manuscript Submission 
Online 
manuscript submission: All manuscripts must be submitted online 
through the new Web site http://www.editorialmanager.com/jog. 
Firsttime 
users: Please click the Register button from the menu and enter the requested 
information. On successful registration, you will be sent an email 
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indicating your user name and 
password. Print a copy of this information for future reference. Note: If you have received an 
email 
from us with an assigned user ID and password, or if you are a repeat user, do not register 
again. Just log in. Once you have an assigned ID and password, you do not have to reregister, 
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even if your status changes (that is, author, reviewer, or editor). Authors: Please click the 
login 
button from the menu at the top of the page and log into the system as an Author. 
Submit your manuscript according to the author instructions. You will be able to track the 
progress of your manuscript through the system. If you experience any problems, please 
contact 
the editorial office. 
Preparation of Manuscript 
Manuscripts that do not adhere to the following instructions will be returned to the 
corresponding author for technical revision before undergoing peer review. 
Copyright Each author must complete and submit the journal's copyright transfer agreement, 
which includes a section on the disclosure of potential conflicts of interest based on the 
recommendations of the International Committee of Medical Journal Editors, "Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals" 
(www.icmje.org/update.html). 
A copy of the form is made available to the submitting author within the Editorial Manager 
submission process. Coauthors 
will automatically receive an Email with instructions on 
completing the form upon submission. 
Title Page 
Include on the title page (a) complete manuscript title; (b) authors' full names, highest 
academic 
degrees, and affiliations; (c) name and address for correspondence, including fax number, 
telephone number, and email 
address; (d) address for reprints if different from that of 
corresponding author; and (e) sources of support that require acknowledgment. 
The title page must also include disclosure of funding received for this work from any of the 
following organizations: National Institutes of Health (NIH); Wellcome Trust; Howard Hughes 
Medical Institute (HHMI); and other(s). This is the first page of your TEXT. 
Structured Abstract and Key Words 
Structured Abstracts are required only for original articles. Key the abstract, doublespaced, 
on a 
separate page following the title page. Limit the abstract to 250 words. Do not cite references 
in 
the abstract. Use the following subheads: Purpose, Patients and Methods (or Materials and 
Methods, Methods, etc., following the structure of the manuscript), Results, and Conclusion(s). 
List three to five key words for indexing. This is the second page of your TEXT. 
Text 
The TEXT portion of your manuscript must be submitted in WORD (.DOC or .DOCX format). 
Organize the manuscript into four main headings: Introduction, Materials and Methods, 
Results, 
and Discussion. Define abbreviations at first mention in text and in each table and figure. If a 
brand name is cited, supply the manufacturer's name and address (city and state/country). 
Acknowledge all forms of support, including pharmaceutical and industry support, in an 
Acknowledgments paragraph. 
Abbreviations 
For a list of standard abbreviations, consult the Council of Biology Editors Style Guide 
(available 
from the Council of Science Editors, 9650 Rockville Pike, Bethesda, MD 20814) or other 
standard 
sources. Write out the full term for each abbreviation at its first use unless it is a standard unit 
of 
measure. Keep abbreviations to the minimum. Do not use abbreviations in the abstract. 
References 
The authors are responsible for the accuracy of the references. Key the references 
(doublespaced) 
at the end of the manuscript. List the references in the order of their citation in the 
manuscript. Cite abstracts and unpublished data, such as papers submitted but not yet 
accepted 
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for publication or personal communications, in parentheses in the text. If there are more than 
three authors, name only the first three authors and then use et al. Refer to the List of 
Journals 
Indexed in Index Medicus for abbreviations of journal names, or access the list at 
http://www.nlm.nih.gov/tsd/serials/lji.html. Sample references are given below: 
Journal article 
1. Budenz DL, Chen PP, Weaver YK. Conjunctival advancement for lateonset 
filtering bleb leaks: 
indications and outcomes. Arch Ophthalmol 1999;117:10141019. 




2. Skuta GL, Morgan RK. Corticosteroidinduced 
glaucoma. In: Ritch R, Shields MB, Krupin T, eds. 
The Glaucomas. St. Louis: Mosby; 1996:11771188. 
Entire book 
3. Gelatt KN, ed. Veterinary Ophthalmology. Philadelphia: Lippincott Williams & Wilkins; 1999. 
Software 




5. Friedman SA. Preeclampsia: a review of the role of prostaglandins. Obstet Gynecol [serial 
online]. January 1988;71:2237. 
Available from: BRS Information Technologies, McLean, VA. 
Accessed December 15, 1990. 
Database 
6. CANCERNETPDQ 
[database online]. Bethesda, MD: National Cancer Institute; 1996. Updated 
March 29, 1996. 
World Wide Web 
7. Gostin LO. Drug use and HIV/AIDS [JAMA HIV/AIDS web site]. June 1, 1996. Available at: 
http://www.amaassn. 
org/special/hiv/ethics. Accessed June 26, 1997. 
Figure/Table legends 
Legends must be submitted for all figures. They should be brief and specific, and they should 
appear on a separate manuscript page after the references. This is the last page of your TEXT. 
Use scale markers in the image for electron micrographs, and indicate the type of stain used. 
Do 
no embed images or tables. This is TEXT only. 
Figures 
Figures must be submitted as individual files, each figure in separate file. They cannot be 
embedded in the word document. Cite figures consecutively in the text, and number them in 
the 
order in which they are discussed. If the images are not of a high enough resolution to permit 
quality reproduction for publication purposes, they will be returned to the author. .TIFF or 
.JPEG 
is the preferred format for Figures. 
Digital art should be created/scanned and saved and submitted as either a TIFF (tagged image 
file format), an EPS (encapsulated postscript) file. Electronic photographsradiographs, 
CT 
scans, and so onand 
scanned images must have a resolution of at least 300 dpi. Line 
art must have a resolution of at least 1200 dpi (dots per inch). If fonts are used in the 
artwork, they must be converted to paths or outlines or they must be embedded in the files. 
Color images must be created/scanned and saved and submitted as CMYK files. 
Color Figures 
The journal accepts for publication color figures that will enhance an article. Authors who 
submit 
color figures will receive an estimate of the cost for color reproduction in print. If they decide 
not 
to pay for color reproduction in print, they can request that the figures be converted to black 
and 
white at no charge. 
All figures supplied in color are published in color online. Figure footnotes are being added to 
figures which appear as color online but not in print. There is only a charge for figures that 
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appear in color in the printed journal. 
Tables 
Cite tables consecutively in the text and number them in that order. Tables must be created 
and 
submitted in WORD (.DOC or .DOCX) format only. Each Table must be submitted in a separate 
file. Each Table should include the table title, appropriate column heads, and explanatory 
legends 
(including definitions of any abbreviations used). Do not embed tables within the body of the 
manuscript. Papers with embedded Tables will be returned to the author for removal prior to 
processing. 
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Supplemental Digital Content 
Supplemental Digital Content (SDC): Authors may submit SDC via Editorial Manager to 
LWW journals that enhance their article's text to be considered for online posting. SDC may 
include standard media such as text documents, graphs, audio, video, etc. On the Attach Files 
page of the submission process, please select Supplemental Audio, Video, or Data for your 
uploaded file as the Submission Item. If an article with SDC is accepted, our production staff 
will 
create a URL with the SDC file. The URL will be placed in the callout 
within the article. SDC files 
are not copyedited 
by LWW staff, they will be presented digitally as submitted. For a list of all 
available file types and detailed instructions, please visit http://links.lww.com/A142. 
SDC Callouts 
Supplemental Digital Content must be cited consecutively in the text of the submitted 
manuscript. Citations should include the type of material submitted (Audio, Figure, Table, 
etc.), 
be clearly labeled as "Supplemental Digital Content," include the sequential list number, and 
provide a description of the supplemental content. All descriptive text should be included in the 
callout 
as it will not appear elsewhere in the article. 
Example: 
We performed many tests on the degrees of flexibility in the elbow (see Video, Supplemental 
Digital Content 1, which demonstrates elbow flexibility) and found our results inconclusive. 
List of Supplemental Digital Content 
A listing of Supplemental Digital Content must be submitted at the end of the manuscript file. 
Include the SDC number and file type of the Supplemental Digital Content. This text will be 
removed by our production staff and not be published. 
Example: 
Supplemental Digital Content 1. wmv 
SDC File Requirements 
All acceptable file types are permissible up to 10 MBs. For audio or video files greater than 10 
MBs, authors should first query the journal office for approval. For a list of all available file 
types 
and detailed instructions, please visit http://links.lww.com/A142. 
Original Articles. All fulllength 
articles will receive at least two editorial peer reviews. Both 
clinical and basic science articles are welcome. Authors are encouraged to limit their paper 
length 
to 18 doublespaced 
typewritten pages. 
Brief Reports. Brief reports with a maximum of two illustrations should be limited to four to six 
typescript pages (including references) that present focused, insightful new clinical or 
investigational observations. Only in very exceptional circumstances does the journal publish 
reports of single cases. 
Case Reports. The journal publishes case reports as onlineonly 
articles. These should be no 
more than six typewritten pages in length. Case reports should be more than interesting or 
unique, but should provide contributory insight into the concepts of management of various 
aspects of glaucoma. 
Compendia of focused glaucoma symposia addressing new information or research strategy of 
special glaucoma interest may be submitted directly to the Editor for consideration in the 
section 
"Symposia." These compendia report important dialogue in letter form, submitted by the 
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symposia moderator, but should not be submitted as original work for editorial review. 
Symposia 
reports should not exceed three typewritten pages. 
Please note that Case Reports and Letters to the Editor will be published online and in the iPad 
app but will not appear in the print issue. They will, however, be listed in the print Table of 
Contents. 
Special Sections. Five special sections emphasize critical focused aspects of glaucoma research 
and care. Many of these are solicited by the Section Editor, but unsolicited manuscripts are 
also 
welcome. Submissions so stipulated will be forwarded to the specific Special Section Editor. 
Therapeutics and Techniques: Short articles on new methods of treatment or new technology. 
Cases in Controversy: A case presentation and management options expressed by three 
glaucomatologists. A review article on the nature of the controversy involved in the case will 
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follow. Glaucoma Care Update: Sociopoliticaleconomic 
issues as they pertain to glaucoma 
management will be addressed. Basic Sciences in Clinical Glaucoma: Review articles putting 
critical basic science work into the perspective of modern glaucoma care. Invited Lectures: 
Invited Honorary Lectures are occasionally published either in their entirety or in abbreviated 
form. These should be submitted directly to the Special Section Editor for editorial review. 
Style 
Pattern manuscript style after American Medical Association Manual of Style (9th edition). 
Stedman's Medical Dictionary (27th edition) and Merriam Webster's Collegiate Dictionary (10th 
edition) should be used as standard references. Refer to drugs and therapeutic agents by their 
accepted generic or chemical names, and do not abbreviate them. Use code numbers only 
when 
a generic name is not yet available. In that case, supply the chemical name and a figure giving 
the chemical structure of the drug. Capitalize the trade names of drugs and place them in 
parentheses after the generic names. To comply with trademark law, include the name and 
location (city and state in USA; city and country outside USA) of the manufacturer of any drug, 
supply, or equipment mentioned in the manuscript. Use the metric system to express units of 
measure and degrees Celsius to express temperatures, and use SI units rather than 
conventional units. 
Authors: Please click the login button from the menu at the top of the page and log in to the 
system as an Author. Submit your manuscript according to the author instructions. You will be 
able to track the progress of your manuscript through the system. If you experience any 
problems, please contact Samantha Z. Porter, Editorial Assistant, (931) 2841843; 
glaucomajournal@outlook.com. 
Submission Check list: 
All authors have signed copyright transfer forms 
The Text portion of your submission is in WORD format. Page 1Title 
Page, Page 2Structured 
Abstract and Keywords 
Cite figures and tables consecutively in your manuscript. TEXT only. Do not embed images or 
tables 
Number figures and tables in the Figure/Table legend in the order in which they are 
discussed. TEXT only 
Upload figures consecutively to the Editorial Manager web site and enter figure numbers 
consecutively in the Description field when uploading the files. .TIFF or .JPEG format 
preferred. Only one figure per file 
Upload Tables consecutively to the Editorial Manager web site and enter table numbers 
consecutively in the Description field when uploading the files. WORD format only. Only one 
table per file 
Electronic page proofs and corrections 
Corresponding authors will receive electronic page proofs to check the copyedited and typeset 
article before publication. Portable document format (PDF) files of the typeset pages and 
support 
documents (e.g., reprint order form) will be sent to the corresponding author via email. 
Complete instructions will be provided with the email 
for downloading and printing the files and 
for faxing the corrected pages to the proof manager (contact information below). 
Corresponding 
author must provide an email address. The proof/correction process is only done electronically. 
It is the author's responsibility to ensure that there are no errors in the proofs. Authors who 
are 
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not native English speakers are strongly encouraged to have their manuscript carefully edited 
by 
a native Englishspeaking 
colleague. Changes that have been made to conform to journal style 
will stand if they do not alter the authors' meaning. Only the most critical changes to the 
accuracy of the content will be made. Changes that are stylistic or are a reworking of 
previously 
accepted material will be disallowed. The publisher reserves the right to deny any changes that 
do not affect the accuracy of the content. Authors may be charged for alterations to the proofs 
beyond those required to correct errors or to answer queries. Electronic proofs must be 
checked 
carefully and corrections faxed within 24 to 48 hours of receipt, as requested in the cover 
letter 
accompanying the page proofs. 
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